DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Togaviridae are 1382

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_0071	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Chikungunya virus	181/25	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_0072	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	181/25	NA	Plaque assay	Decrease (50 %)	Approved	28240606
DrugRepV_0185	Nanchangmycin	Antibacterial; Antiviral	NA	Chikungunya virus	181/25	NA	Real-time PCR	Decrease (95 %)	NA	28099856
DrugRepV_0192	Nanchangmycin	Antibacterial; Antiviral	NA	Chikungunya virus	Mex2-81	NA	TCID50 assay	Decrease (90 %)	NA	28099856
DrugRepV_0193	Nanchangmycin	Antibacterial; Antiviral	NA	Chikungunya virus	Mex2-81	NA	TCID50 assay	Decrease (95 %)	NA	28099856
DrugRepV_0194	Nanchangmycin	Antibacterial; Antiviral	NA	Chikungunya virus	Mex2-81	NA	TCID50 assay	Decrease (95 %)	NA	28099856
DrugRepV_1966	Lanatoside C	Cardiovascular agents	Arrhythmia	Chikungunya virus	NA	NA	Plaque assay	Decrease (38.66 %)	Experimental	25251726
DrugRepV_2054	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Chikungunya virus	S27	NA	Real-time PCR	Decrease (50 %)	Approved	27742486
DrugRepV_2055	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Chikungunya virus	S27	NA	Real-time PCR	Decrease (50 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2056	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Chikungunya virus	S27	NA	Immunoflourescence assay	Decrease	Approved	27742486
DrugRepV_2057	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Chikungunya virus	S27	NA	Immunoflourescence assay	Decrease	Approved, Investigational, Vet approved	27742486
DrugRepV_2058	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Chikungunya virus	0611aTw	NA	Real-time PCR	Decrease (50 %)	Approved	27742486
DrugRepV_2059	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Chikungunya virus	0611aTw	NA	Real-time PCR	Decrease (50 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2060	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Chikungunya virus	081bTw	NA	Real-time PCR	Decrease (50 %)	Approved	27742486
DrugRepV_2061	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Chikungunya virus	081bTw	NA	Real-time PCR	Decrease (50 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2062	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Chikungunya virus	S27	NA	Real-time PCR	Decrease (50 %)	Approved	27742486
DrugRepV_2063	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Chikungunya virus	S27	NA	Real-time PCR	Decrease (50 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2064	Niflumic Acid	Musculo-Skeletal System	Rheumatoid arthritis	Chikungunya virus	S27	NA	Microneutralization assay	No significant decrease	Approved	27742486
DrugRepV_2065	Tolfenamic Acid	Musculo-Skeletal System	Pain associated with the acute attack of migraines	Chikungunya virus	S27	NA	Microneutralization assay	No significant decrease	Approved, Investigational	27742486
DrugRepV_2156	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Decrease (96.1181392 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2157	Nitrofurazone	Blood and Blood Forming Organs; Dermatologicals; Dermatologicals; Antiparasitic products, Insectisid	Bacterial skin infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Decrease (92.2011022 %)	Approved	27742486
DrugRepV_2158	Tolfenamic Acid	Musculo-Skeletal System	Pain associated with the acute attack of migraines	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Decrease (91.0134313 %)	Approved, Investigational	27742486
DrugRepV_2159	Flunixin Meglumin	Anti-inflammatory	Anti-inflammatory agent (used in animals)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Decrease (57.8934305 %)	NA	27742486
DrugRepV_2160	Calcitriol	Alimentary Tract and Metabolism	Vitamin D deficiency	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Decrease (57.47978 %)	Approved	27742486
DrugRepV_2161	Atovaquone	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Decrease (55.760271 %)	Approved	27742486
DrugRepV_2162	Epalrestat	Anti-diabetic	Diabetic neuropathy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Decrease (54.8385744 %)	Investigational	27742486
DrugRepV_2163	Levosimendan	Cardiovascular agents	Chronic heart failure (CHF) | Heart disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Decrease (54.4775159 %)	Approved, Investigational	27742486
DrugRepV_2164	Menadione	Blood and Blood Forming Organs	Blood clotting | Bone calcification	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Decrease (54.2699321 %)	Approved, Nutraceutical	27742486
DrugRepV_2165	Repaglinide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (48.7632872 %)	Approved, Investigational	27742486
DrugRepV_2166	Azilsartan Medoxomil	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (42.534615 %)	Approved	27742486
DrugRepV_2167	Diclofenac Diethylamine	Dermatologicals; Musculo-Skeletal System and Sensory Organ	Osteoarthritis and rheumatoid arthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (40.6760631 %)	Approved	27742486
DrugRepV_2168	Nimesulide	Musculo-Skeletal System	Acute pain | Symptomatic treatment of osteoarthritis | Primary dysmenorrhoea	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (39.2301835 %)	Approved, Investigational, Withdrawn	27742486
DrugRepV_2169	Acemetacin	Musculo-Skeletal System	Acute inflammation of the joints - Analgesic and antipyretic	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (39.1366729 %)	Approved	27742486
DrugRepV_2170	Diclofenac Potassium	Dermatologicals; Musculo-Skeletal System and Sensory Organ	Fever and pain	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (38.1915639 %)	Approved	27742486
DrugRepV_2171	Lonidamine	Antineoplastic and Immunomodulating Agents	Benign prostatic hyperplasia | Prostate disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (35.3539647 %)	Investigational	27742486
DrugRepV_2172	Azilsartan	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (33.7555588 %)	Approved	27742486
DrugRepV_2173	Candesartan cilexetil	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (19.4231062 %)	Approved	27742486
DrugRepV_2174	Aprepitant	Alimentary Tract and Metabolism	Nausea and vomiting	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (18.8613362 %)	Approved	27742486
DrugRepV_2175	Fluvastatin Sodium	Cardiovascular agents	Cardiovascular disease (Coronary heart disease (CHD))	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (18.5093019 %)	Approved	27742486
DrugRepV_2176	Pizotifen Malate	Nervous System	Migraines	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (16.7563948 %)	Approved	27742486
DrugRepV_2177	Avobenzone	NA	Sunburn	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (16.643533 %)	Approved	27742486
DrugRepV_2178	Mitoxantrone Hydrochloride	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (15.1626877 %)	Approved, Investigational	27742486
DrugRepV_2179	Irinotecan Hydrochloride Trihydrate	Antineoplastic and Immunomodulating Agents	Colorectal cancer | Small cell lung cancer | Cervical cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (14.6383286 %)	Approved, Investigational	27742486
DrugRepV_2180	Azelastine Hydrochloride	Respiratory System	Rhinitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (14.2513127 %)	Approved	27742486
DrugRepV_2181	Lovastatin	Cardiovascular agents	Atherosclerotic vascular disease | Hypercholesterolemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (14.1848079 %)	Approved, Investigational	27742486
DrugRepV_2182	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Ovulatory Dysfunction	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (14.0147255 %)	Approved	27742486
DrugRepV_2183	Oxfendazole	Antiparasitic	Protects livestock from roundworm. strongyles, and pinworn	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (13.9350528 %)	Approved	27742486
DrugRepV_2184	Estradiol Valerate	Genito Urinary System and Sex Hormones	Vulvar and vaginal atrophy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (13.5411627 %)	Approved	27742486
DrugRepV_2185	Etidronate	Musculo-Skeletal System	Paget disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (13.5390608 %)	Approved	27742486
DrugRepV_2186	Abiraterone	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (12.7697585 %)	Approved	27742486
DrugRepV_2187	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (12.5546344 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2188	Methylprednisolone	Dermatologicals; Dermatologicals; Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Rheumatoid arthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (11.8062257 %)	Approved, Vet approved	27742486
DrugRepV_2189	Scopolamine Hydrobromide	Alimentary Tract And Metabolism; Nervous System; Sensory Organ	Irritable bowel syndrome | Excessive salivation | Motion sickness	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (11.8009385 %)	Approved, Investigational	27742486
DrugRepV_2190	Neostigmine Bromide	Nervous System	Myasthenia gravis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (11.3329876 %)	Approved	27742486
DrugRepV_2191	L-Thyroxine	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hypothyroidism	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (10.9745889 %)	Approved	27742486
DrugRepV_2192	Ziprasidone Hydrochloride	Nervous System	Schizophrenia and psychotic disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (10.899998 %)	Approved	27742486
DrugRepV_2193	Fenofibrate	Cardiovascular agents	Hypercholesterolemia | Dyslipidemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (10.8996039 %)	Approved	27742486
DrugRepV_2194	Nateglinide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (10.5810833 %)	Approved, Investigational	27742486
DrugRepV_2195	Fluoxetine Hydrochloride	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (10.4504102 %)	Approved, Vet approved	27742486
DrugRepV_2196	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (10.2727802 %)	Approved	27742486
DrugRepV_2197	Olanzapine	Nervous System	Schizophrenia | Bipolar I disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (10.0723372 %)	Approved, Investigational	27742486
DrugRepV_2198	Neomycin Sulfate	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (10.0220837 %)	Approved	27742486
DrugRepV_2199	Brompheniramine	Respiratory System	Allergies, rhinitis and urticaria	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (9.75770133 %)	Approved	27742486
DrugRepV_2200	Rifampin	Antiinfectives For Systemic Use	Tuberculosis and Tuberculosis-related mycobacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (9.11795232 %)	Approved	27742486
DrugRepV_2201	Atazanavir Sulfate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (8.91119067 %)	Approved	27742486
DrugRepV_2202	Miconazole Nitrate	Alimentary Tract And Metabolism; Dermatologicals; Genito Urinary System; Sex Hormones; Antiinfective	Fungal infections (Tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment o	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (8.84799674 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2203	Vorinostat	Antineoplastic and Immunomodulating Agents	T-cell lymphoma (CTCL, a type of cancer)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (8.83658563 %)	Approved	27742486
DrugRepV_2204	Dimethyl Fumarate	Anti-inflammatory	Multiple sclerosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (8.81629076 %)	Approved	27742486
DrugRepV_2205	Tiopronin	Genito Urinary System and Sex Hormones	Kidney stone	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (8.70633878 %)	Approved	27742486
DrugRepV_2206	Dutasteride	Genito Urinary System and Sex Hormones	Prostatic hyperplasia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (8.1427081 %)	Approved	27742486
DrugRepV_2207	Ritodrine Hydrochloride	Genito Urinary System and Sex Hormones	Premature labour	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (8.00664706 %)	Approved, Investigational	27742486
DrugRepV_2208	Dipyridamole	Blood and Blood Forming Organs	Coagulation disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.91414617 %)	Approved	27742486
DrugRepV_2209	Proparacaine Hydrochloride	Sensory Organ	Ophthalmic anesthetic	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.83586814 %)	Approved, Vet approved	27742486
DrugRepV_2210	Pefloxacin Mesylate	Antiinfectives For Systemic Use	Gonococcal urethritis in males	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.83586814 %)	Approved	27742486
DrugRepV_2211	Ranolazine Dihydrochloride	Cardiovascular agents	Chronic angina | Ventricular tachycardia | Acute coronary syndrome | Microvascular coronary dysfunction | Arrhythmia | Glycemic control	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.80000539 %)	Approved	27742486
DrugRepV_2212	Butenafine Hydrochloride	Dermatologicals	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.76085859 %)	Approved	27742486
DrugRepV_2213	Diphenhydramine Hydrochloride	Dermatologicals and Respiratory System	Vertigo/Meniere disease, nausea and vomiting, motion sickness and insect bite	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.67086 %)	Approved	27742486
DrugRepV_2214	Moroxydine	Antiinfectives For Systemic Use	Influenza	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.65475751 %)	Experimental	27742486
DrugRepV_2215	Fudosteine	NA	Bronchial asthma | Chronic bronchitis | Pulmonary emphysema | Bronchiectasis | Pulmonary tuberculosis | Pneumoconiosis | Atypical mycobacterial disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.62256156 %)	NA	27742486
DrugRepV_2216	Pranlukast	Respiratory System	Allergic reaction	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.56691777 %)	Approved	27742486
DrugRepV_2217	Etodolac	Musculo-Skeletal System	Osteoarthritis and rheumatoid arthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.54969898 %)	Approved	27742486
DrugRepV_2218	Trifluridine	Sensory Organ	Primary keratoconjunctivitis and Herpes simplex keratitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.43774052 %)	Approved	27742486
DrugRepV_2219	Oxymetazoline Hydrochloride	Sensory Organ	Eye irritation	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.399478 %)	Approved, Investigational	27742486
DrugRepV_2220	Tylosin tartrate	NA	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.36358127 %)	Vet Approved	27742486
DrugRepV_2221	Doxercalciferol	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Secondary hyperparathyroidism	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.31888883 %)	Approved	27742486
DrugRepV_2222	Fenoprofen Calcium	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.30740883 %)	Approved	27742486
DrugRepV_2223	Methoxsalen	Dermatologicals	Psoriasis | Vitiligo	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.14420741 %)	Approved	27742486
DrugRepV_2224	Anastrozole	Antineoplastic and Immunomodulating Agents	Breast cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.12964085 %)	Approved	27742486
DrugRepV_2225	Ozagrel	Ophthalmic-agent	Dry eye syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.09023957 %)	Investigational	27742486
DrugRepV_2226	Gefitinib	Antineoplastic and Immunomodulating Agents	Non-small cell lung cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.05142618 %)	Approved, Investigational	27742486
DrugRepV_2227	Pirarubicin	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.04365539 %)	Investigational	27742486
DrugRepV_2228	Fulvestrant	Antineoplastic and Immunomodulating Agents	Breast cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.04032324 %)	Approved, Investigational	27742486
DrugRepV_2229	Clozapine	Nervous System	Psychosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.00172882 %)	Approved	27742486
DrugRepV_2230	Oxibendazole	Antiparasitic	Helminth intestinal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.98667471 %)	Investigational, Vet approved	27742486
DrugRepV_2231	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.95397975 %)	Approved	27742486
DrugRepV_2232	Lapatinib Ditosylate	Antineoplastic and Immunomodulating Agents	Breast cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.93254343 %)	Approved, Investigational	27742486
DrugRepV_2233	Reserpine	Cardiovascular agents	Hypertension | Psychotic disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.9045194 %)	Approved, Investigational	27742486
DrugRepV_2234	Rifaximin	Alimentary Tract and Metabolism	Traveller's Diarrhea | Irritable bowel syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.80622494 %)	Approved, Investigational	27742486
DrugRepV_2235	Arbidol Hydrochloride	NA	Influenza	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.59070859 %)	NA	27742486
DrugRepV_2236	Mianserin Hydrochloride	Nervous System	Depression	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.5508974 %)	Approved, Investigational	27742486
DrugRepV_2237	Terbinafine Hydrochloride	Dermatologicals	Toenail or Fingernail infections (Fungal) | Tinea capitis (scalp ringworm) | Tinea corporis (body ringworm) or tinea cruris (jock itch)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.51264741 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2238	Clemastine Fumarate	Respiratory System	Allergic rhinitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.50989786 %)	Approved	27742486
DrugRepV_2239	Acipimox	Cardiovascular agents	Hyperlipidemias	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.42097206 %)	Approved	27742486
DrugRepV_2240	Itraconazole	Antiinfectives For Systemic Use	Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.35827197 %)	Approved, Investigational	27742486
DrugRepV_2241	Novobiocin Sodium	NA	Staphylococci infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.24445866 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2242	Asenapine	Nervous System	Psychosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.19909164 %)	Approved	27742486
DrugRepV_2243	5-Aminolevulinic Acid Hydrochloride	Antineoplastic and Immunomodulating Agents	Actinic keratoses	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.19454622 %)	Approved	27742486
DrugRepV_2244	Azacyclonol	NA	Psychosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.14203789 %)	NA	27742486
DrugRepV_2245	Methenamine	Antiinfectives For Systemic Use	Urinary tract infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.11366498 %)	Approved, Vet approved	27742486
DrugRepV_2246	Azithromycin	Antiinfectives For Systemic Use	Microbial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.11366498 %)	Approved	27742486
DrugRepV_2247	Sunitinib Malate	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.08231961 %)	Approved, Investigational	27742486
DrugRepV_2248	Tropicamide	Sensory Organ	Mydriasis and Cycloplegia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.04488039 %)	Approved	27742486
DrugRepV_2249	Praziquantel	Antiparasitic products, Insectisides and Repellents	Schistosomiasis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.93918289 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2250	Celecoxib	Musculo-Skeletal System	Osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.89285907 %)	Approved	27742486
DrugRepV_2251	Ibandronate Sodium	Musculo-Skeletal System	Osteoporosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.8438752 %)	Approved, Investigational	27742486
DrugRepV_2252	Phenytoin	Nervous System	Seizures	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.83857713 %)	Approved, Vet approved	27742486
DrugRepV_2253	Beta-Carotene	Alimentary Tract And Metabolism; Dermatologicals	Nutrient supplement	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.82798788 %)	Approved	27742486
DrugRepV_2254	Resveratrol	Anticancer	Herpes labialis infections (cold sores)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.82320541 %)	Approved, Experimental, Investigational	27742486
DrugRepV_2255	Deferasirox	Various	Tansfusional hemosiderosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.76811009 %)	Approved	27742486
DrugRepV_2256	Captopril	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.73529808 %)	Approved	27742486
DrugRepV_2257	Pyrimethamine	Antiparasitic products, Insectisides and Repellents	Toxoplasmosis | Acute malaria	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.73171647 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2258	Biapenem	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.72083061 %)	Investigational	27742486
DrugRepV_2259	Lidocaine	Cardiovascular agents	Anesthesia | Ventricular arrhythmias	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.70999199 %)	Approved, Vet approved	27742486
DrugRepV_2260	Calcium Levofolinate	Various	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.51423322 %)	NA	27742486
DrugRepV_2261	Azasetron Hydrochloride	NA	Nausea and vomiting induced by cancer chemotherapy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.49334625 %)	NA	27742486
DrugRepV_2262	Primidone	Nervous System	Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.34861552 %)	Approved, Vet approved	27742486
DrugRepV_2263	Idoxuridine	Antiinfectives For Systemic Use	Keratoconjunctivitis and Keratitis caused by herpes simplex virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.28034643 %)	Approved, Investigational	27742486
DrugRepV_2264	Ellagic Acid	Antioxidant and Anti-proliferative	Follicular Lymphoma, brain injury in intrauterine growth restricted babies, obese adolescents, and solar lentigines	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.26155613 %)	Approved	27742486
DrugRepV_2265	Clindamycin Phosphate	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.23907349 %)	Approved	27742486
DrugRepV_2266	Nisoldipine	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.19489422 %)	Approved	27742486
DrugRepV_2267	Conivaptan Hydrochloride	Cardiovascular agents	Hypervolemic hyponatremia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.13797577 %)	Approved	27742486
DrugRepV_2268	Pancuronium	Musculo-Skeletal System	Muscle relaxant during anesthesia and surgical procedures	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.07557498 %)	Approved	27742486
DrugRepV_2269	Tigecycline	Antiinfectives For Systemic Use	Complicated skin and skin structure infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.03969688 %)	Approved	27742486
DrugRepV_2270	Trimebutine	Alimentary Tract and Metabolism	Irritable bowel syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.01937948 %)	Approved	27742486
DrugRepV_2271	Isotretinoin	Dermatologicals	Acne	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.00736344 %)	Approved	27742486
DrugRepV_2272	Flumazenil	Various	Anesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.99459989 %)	Approved	27742486
DrugRepV_2273	Clobetasol Propionate	Dermatologicals	Psoriasis and dermatosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.9664796 %)	Approved	27742486
DrugRepV_2274	Roxatidine Acetate Hydrochloride	Alimentary Tract and Metabolism	Gastro-intestinal disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.9480885 %)	Experimental	27742486
DrugRepV_2275	Drospirenone	Genito Urinary System and Sex Hormones	Contraception	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.94004334 %)	Approved	27742486
DrugRepV_2276	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.92265574 %)	Approved, Investigational	27742486
DrugRepV_2277	Econazole Nitrate	Dermatologicals	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.89847179 %)	Approved	27742486
DrugRepV_2278	Cisatracurium Besylate	Musculo-Skeletal System	Muscle spasms	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.8029401 %)	Approved	27742486
DrugRepV_2279	Cyproheptadine Hydrochloride	Respiratory System	Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.78644356 %)	Approved	27742486
DrugRepV_2280	OSI-420	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.78127734 %)	NA	27742486
DrugRepV_2281	Antipyrine	Nervous System	Analgesic	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.7739269 %)	Approved	27742486
DrugRepV_2282	Doripenem Hydrate	Antiinfectives For Systemic Use	Intra-abdominal infections and complicated urinary tract infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.71564204 %)	Approved	27742486
DrugRepV_2283	Sulfamethazine	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, prostatitis and urinary tract infections)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.70881807 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2284	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.70566399 %)	Approved	27742486
DrugRepV_2285	Aminoglutethimide	Antineoplastic and Immunomodulating Agents	Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.69804317 %)	Approved	27742486
DrugRepV_2286	Roflumilast	Respiratory System	Chronic Obstructive Pulmonary Disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.69383115 %)	Approved	27742486
DrugRepV_2287	Iloperidone	Nervous System	Schizophrenia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.68190957 %)	Approved	27742486
DrugRepV_2288	Erlotinib Hydrochloride	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.66114654 %)	Approved	27742486
DrugRepV_2289	Minoxidil	Cardiovascular agents; Dermatologicals	Hypertension | Alopecia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.65421085 %)	Approved, Investigational	27742486
DrugRepV_2290	Ifosfamide	Antineoplastic and Immunomodulating Agents	Germ cell testicular cancer | Cervical cancer | Osteosarcoma | Bladder cancer | Ovarian cancer | Small cell lung cancer | Non-Hodgkin's lymphoma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.62298755 %)	Approved	27742486
DrugRepV_2291	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.58224242 %)	Approved	27742486
DrugRepV_2292	Probucol	Cardiovascular agents	LDL and HDL cholesterol	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.54118117 %)	Approved, Investigational	27742486
DrugRepV_2293	Mepivacaine Hydrochloride	Nervous System	Analgesia | Anesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.51844444 %)	Approved, Vet approved	27742486
DrugRepV_2294	Daidzein	NA	Dietary supplement	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.45147852 %)	Experimental	27742486
DrugRepV_2295	Haloperidol	Nervous System	Schizophrenia | Psychotic disorders | Chemotherapy-induced nausea/vomiting	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.44529073 %)	Approved	27742486
DrugRepV_2296	Adenine Hydrochloride	NA	Nutritional supplement	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.42334798 %)	Approved	27742486
DrugRepV_2297	Tianeptine Sodium	Nervous System	Depressive disorder | Irritable bowel syndrome (IBS)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.41872904 %)	Investigational	27742486
DrugRepV_2298	Thioguanine	Antineoplastic and Immunomodulating Agents	Acute leukemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.41764454 %)	Approved	27742486
DrugRepV_2299	Sulfapyridine	Antiinfectives For Systemic Use	Dermatitis herpetiformis | Benign mucous membrane pemphigoid | Pyoderma gangrenosum	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.40977237 %)	Approved	27742486
DrugRepV_2300	Lubiprostone	Alimentary Tract and Metabolism	Constipation | Irritable bowel syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.40977237 %)	Approved, Investigational	27742486
DrugRepV_2301	Thiamphenicol	Antiinfectives For Systemic Use	Infectious diseases in cattle, pigs and poultry)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.40312446 %)	Experimental, Investigational	27742486
DrugRepV_2302	Tropisetron	Alimentary Tract and Metabolism	Nausea and vomiting	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.39903618 %)	Approved	27742486
DrugRepV_2303	Aniracetam	Nervous System	Psychosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.38872845 %)	Experimental	27742486
DrugRepV_2304	Levamisole Hydrochloride	Antiparasitic products, Insectisides and Repellents	Helminthiasis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.33501607 %)	Approved, Investigational, Vet approved, Withdrawn	27742486
DrugRepV_2305	Sotalol	Cardiovascular agents	Atrial flutter	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.33498865 %)	Approved	27742486
DrugRepV_2306	Pemetrexed	Antineoplastic and Immunomodulating Agents	Cancer (Chemotherapy drug) | Malignant pleural mesothelioma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.33026007 %)	Approved, Investigational	27742486
DrugRepV_2307	Loratadine	Respiratory System	Rhinitis | Urticaria	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.27362909 %)	Approved, Investigational	27742486
DrugRepV_2308	Urapidil Hydrochloride	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.25520328 %)	Investigational	27742486
DrugRepV_2309	Vinpocetine	Nervous System	Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.10031537 %)	Investigational	27742486
DrugRepV_2310	Sulfamethizole	Antiinfectives For Systemic Use	Urinary tract infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.08218845 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2311	Inulin	Various	Diabetes mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.04438602 %)	Approved, Investigational, Nutraceutical	27742486
DrugRepV_2312	Betamethasone Valerate	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Dermatoses	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.99594087 %)	Approved	27742486
DrugRepV_2313	Ritonavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.98622242 %)	Approved, Investigational	27742486
DrugRepV_2314	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.96247894 %)	Approved	27742486
DrugRepV_2315	Memantine Hydrochloride	Nervous System	Alzheimer's dementia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.94665072 %)	Approved, Investigational	27742486
DrugRepV_2316	Etomidate	Nervous System	General anesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.92770767 %)	Approved	27742486
DrugRepV_2317	Cytarabine	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.9061166 %)	Approved	27742486
DrugRepV_2318	Lenalidomide	Antineoplastic and Immunomodulating Agents	Multiple myeloma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.87586362 %)	Approved	27742486
DrugRepV_2319	Teniposide	Antineoplastic and Immunomodulating Agents	Acute lymphoblastic leukaemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.85778554 %)	Approved	27742486
DrugRepV_2320	Pioglitazone Hydrochloride	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.84924548 %)	Approved, Investigational	27742486
DrugRepV_2321	Medroxyprogesterone Acetate	Genito Urinary System and Sex Hormones	Amenorrhea | Abnormal uterine bleeding	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.84716499 %)	Approved	27742486
DrugRepV_2322	Hydroxyurea	Antineoplastic and Immunomodulating Agents	Melanoma | Chronic myelocytic leukemia | Ovary carcinoma | Sickle-cell anemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.83370655 %)	Approved	27742486
DrugRepV_2323	Geniposide	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.7860683 %)	NA	27742486
DrugRepV_2324	Isoniazid	Antiinfectives For Systemic Use	Tuberculosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.74356574 %)	Approved, Investigational	27742486
DrugRepV_2325	Lapatinib	Antineoplastic and Immunomodulating Agents	Breast cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.71161747 %)	Approved, Investigational	27742486
DrugRepV_2326	Dyclonine Hydrochloride	Nervous System	Anesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.70472644 %)	Approved	27742486
DrugRepV_2327	Moxonidine	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.70472644 %)	Approved, Investigational	27742486
DrugRepV_2328	Ketoconazole	Antiinfectives For Systemic Use	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.68563359 %)	Approved, Investigational	27742486
DrugRepV_2329	Chloroxine	NA	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.67704383 %)	Approved	27742486
DrugRepV_2330	Rosiglitazone	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.65071465 %)	Approved	27742486
DrugRepV_2331	Milnacipran Hydrochloride	Nervous System	Depressive disorder | Fibromyalgia pain	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.63202363 %)	Approved, Investigational	27742486
DrugRepV_2332	Metformin Hydrochloride	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.60501062 %)	Approved	27742486
DrugRepV_2333	Chenodiol	Alimentary Tract and Metabolism	Radiolucent Cholestrol gallstones	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.59183631 %)	Approved	27742486
DrugRepV_2334	Finasteride	Genito Urinary System and Sex Hormones	Benign prostatic hyperplasia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.57558611 %)	Approved	27742486
DrugRepV_2335	Lornoxicam	Musculo-Skeletal System	Pain	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.49164883 %)	Approved, Investigational	27742486
DrugRepV_2336	Omeprazole	Alimentary Tract and Metabolism	Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.4755509 %)	Approved	27742486
DrugRepV_2337	Adiphenine Hydrochloride	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.4400476 %)	NA	27742486
DrugRepV_2338	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.43393568 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2339	Dienogest	Genito Urinary System and Sex Hormones	Endometriosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.3635241 %)	Approved	27742486
DrugRepV_2340	Formoterol Hemifumarate	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.36046959 %)	Approved, Investigational	27742486
DrugRepV_2341	Gadodiamide	Various	Intravenous use in MRI to visualize lesions	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.33933034 %)	Approved, Investigational	27742486
DrugRepV_2342	Fluocinolone Acetonide	Cardiovascular agents; Dermatologicals; Sensory Organ; Sensory Organ	Chronic non-infectious uveitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.307845 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2343	Protionamide	Antiinfectives For Systemic Use	MDR-TB | Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.29332873 %)	Approved, Investigational	27742486
DrugRepV_2344	Doxazosin Mesylate	Cardiovascular agents	Hypertension and Hyperplasia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.283278 %)	Approved	27742486
DrugRepV_2345	Meptazinol Hydrochloride	Nervous System	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.28059603 %)	Experimental	27742486
DrugRepV_2346	Imatinib Mesylate	Antineoplastic and Immunomodulating Agents	Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.27014953 %)	Approved	27742486
DrugRepV_2347	Amoxicillin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.26461637 %)	Approved	27742486
DrugRepV_2348	Ciclopirox	Dermatologicals	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.26315249 %)	Approved	27742486
DrugRepV_2349	Phenylephrine Hydrochloride	Cardiovascular agents; Respiratory System; Sensory Organ	Nasal congestion | Hypotension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.23716921 %)	Approved	27742486
DrugRepV_2350	Tranexamic Acid	Blood and Blood Forming Organs	Hemorrhage	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.23343185 %)	Approved	27742486
DrugRepV_2351	Loperamide Hydrochloride	Alimentary Tract and Metabolism	Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.23233156 %)	Approved	27742486
DrugRepV_2352	Pramiracetam	Antipsychotic	Alzheimer's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.22427984 %)	Approved	27742486
DrugRepV_2353	Etoposide	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.1881398 %)	Approved	27742486
DrugRepV_2354	Cephradine	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.17042436 %)	Approved	27742486
DrugRepV_2355	Methylthiouracil	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hyperthyroidism	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.1440867 %)	Experimental	27742486
DrugRepV_2356	Metoprolol Tartrate	Cardiovascular agents	Angina | Heart failure | Myocardial infarction | Atrial fibrillation | Atrial flutter | Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.12858015 %)	Approved, Investigational	27742486
DrugRepV_2357	Mecarbinate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.00956049 %)	NA	27742486
DrugRepV_2358	Sitafloxacin Hydrate	Antiinfectives For Systemic Use	Bacterial infections (respiratory and urinary tract infections)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.96036077 %)	Experimental, Investigational	27742486
DrugRepV_2359	Nefiracetam	Neurologic-agent	Alzheimer's Disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.954445 %)	Investigational	27742486
DrugRepV_2360	Enoxacin	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.93176568 %)	Approved	27742486
DrugRepV_2361	Quetiapine Fumarate	Nervous System	Schizophrenia | Bipolar disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.90178299 %)	Approved	27742486
DrugRepV_2362	Allopurinol Sodium	Musculo-Skeletal System	Hyperuricemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.87428814 %)	Approved	27742486
DrugRepV_2363	Clofibrate	Cardiovascular agents	Hyperlipoproteinemia type III	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.86775626 %)	Approved	27742486
DrugRepV_2364	Olopatadine Hydrochloride	Sensory Organ	Allergic conjunctivitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.86546695 %)	Approved	27742486
DrugRepV_2365	Benztropine Mesylate	Nervous System	Parkinson disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.84775979 %)	Approved	27742486
DrugRepV_2366	Dorzolamide Hydrochloride	Sensory Organ	Open-angle glaucoma and ocular hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.81420444 %)	Approved	27742486
DrugRepV_2367	Buflomedil Hydrochloride	Cardiovascular agents	Claudication and peripheral arterial disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.79867437 %)	NA	27742486
DrugRepV_2368	Ampicillin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.75763916 %)	Approved	27742486
DrugRepV_2369	Duloxetine Hydrochloride	Nervous System	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.74588077 %)	Approved	27742486
DrugRepV_2370	Cytidine	NA	Biopolar Depression	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.69043453 %)	Experimental	27742486
DrugRepV_2371	Bromhexine Hydrochloride	Respiratory System	Respiratory disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.68488038 %)	Approved	27742486
DrugRepV_2372	Adapalene	Dermatologicals	Acne vulgaris	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.66633546 %)	Approved	27742486
DrugRepV_2373	Clorsulon	Veterinary medicine	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.66288958 %)	Vet approved	27742486
DrugRepV_2374	Enalaprilat Dihydrate	Cardiovascular Agents	Hypertension and symptomatic congestive heart failure	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.61173617 %)	Approved	27742486
DrugRepV_2375	Bicalutamide	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.5677801 %)	Approved	27742486
DrugRepV_2376	Ozagrel Hydrochloride	Ophthalmic-agent	Dry eye syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.56463314 %)	Investigational	27742486
DrugRepV_2377	Azatadine Dimaleate	Respiratory System	Respiratory mucosal congestion and allergic rhinitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.55959216 %)	Approved	27742486
DrugRepV_2378	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.53351293 %)	Approved	27742486
DrugRepV_2379	Fluticasone propionate	Respiratory System	Asthma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.49959478 %)	Approved	27742486
DrugRepV_2380	Alfuzosin Hydrochloride	Genito Urinary System and Sex Hormones	Benign prostatic hyperplasia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.46993265 %)	Approved	27742486
DrugRepV_2381	Niacin	NA	Hyperlipidemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.44049164 %)	Approved, Investigational, Nutraceutical	27742486
DrugRepV_2382	Cleviprex	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.43173855 %)	Approved	27742486
DrugRepV_2383	Bacitracin Zinc	Antiinfectives For Systemic Use	Pneumonia and empyema	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.42855269 %)	Approved	27742486
DrugRepV_2384	Potassium Iodide	Sensory Organ; Various	Hyperthyroidism | Thyrotoxicosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.4041496 %)	Approved	27742486
DrugRepV_2385	Meclizine Dihydrochloride	Respiratory System	Nausea | Vomiting | Motion sickness | Vertigo	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.40144725 %)	Approved	27742486
DrugRepV_2386	Gliquidone	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.39646573 %)	Approved	27742486
DrugRepV_2387	Risedronic Acid	Musculo-Skeletal System	Paget's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.38707257 %)	Approved	27742486
DrugRepV_2388	Albendazole oxide	NA	Parasitic infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.36721682 %)	Experimental	27742486
DrugRepV_2389	Temocapril Hydrochloride	Cardiovascular agents	Hypertension | Congestive heart failure | Diabetic nephropathy | Improvement of prognosis for coronary artery diseases	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.35963363 %)	Experimental, Investigational	27742486
DrugRepV_2390	Argatroban	Blood and Blood Forming Organs	Coagulation disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.35584553 %)	Approved	27742486
DrugRepV_2391	Clonidine Hydrochloride	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.34543683 %)	Approved	27742486
DrugRepV_2392	Geniposidic Acid	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.33842957 %)	NA	27742486
DrugRepV_2393	Cyclophosphamide Monohydrate	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.30836213 %)	Approved	27742486
DrugRepV_2394	Nebivolol	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.30490861 %)	Approved, Investigational	27742486
DrugRepV_2395	Apatinib	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.2767148 %)	Investigational	27742486
DrugRepV_2396	Trichlormethiazide	Cardiovascular agents	Oedema and Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.27400898 %)	Approved	27742486
DrugRepV_2397	Lafutidine	Alimentary Tract and Metabolism	Peptic Ulcer | Pneumonia | Gastroesophageal Reflux Disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.27113814 %)	Investigational	27742486
DrugRepV_2398	Trilostane	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Cushing's syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.24049946 %)	Approved	27742486
DrugRepV_2399	Paeoniflorin	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.22636429 %)	NA	27742486
DrugRepV_2400	Lansoprazole	Alimentary Tract and Metabolism	Gastric acid secretion | Gastric ulcers, active duodenal ulcers | Erosive reflux oesophagitis | Gastroesophageal reflux disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.21219908 %)	Approved, Investigational	27742486
DrugRepV_2401	Budesonide	Alimentary Tract And Metabolism; Dermatologicals; Respiratory System; Respiratory System	Crohn disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.20587616 %)	Approved	27742486
DrugRepV_2402	Strontium Ranelate	Musculo-Skeletal System	Osteoporosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.19592095 %)	Approved, Withdrawn	27742486
DrugRepV_2403	Clindamycin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.19411786 %)	Approved	27742486
DrugRepV_2404	Spectinomycin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections (Gonorrheal urethritis and proctitis)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.18634054 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2405	Nicorandil	Cardiovascular agents	Acute coronary syndromes	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.17516391 %)	Approved, Investigational	27742486
DrugRepV_2406	Mizolastine	Respiratory System	Allergic rhinitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.16794907 %)	Investigational	27742486
DrugRepV_2407	Adenine	NA	Nutritional supplement	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.12499687 %)	Approved	27742486
DrugRepV_2408	Decitabine	Antineoplastic and Immunomodulating Agents	Myelodysplastic syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.12473547 %)	Approved	27742486
DrugRepV_2409	Epinephrine Bitartrate	Alimentary Tract And Metabolism; Blood and Blood Forming Organs; Cardiovascular agents; Respiratory	Severe allergic reactions (including anaphylaxis)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.09263056 %)	Approved	27742486
DrugRepV_2410	Clomipramine Hydrochloride	Nervous System	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.09263056 %)	Approved	27742486
DrugRepV_2411	Bexarotene	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.0549399 %)	Approved	27742486
DrugRepV_2412	Meloxicam	Musculo-Skeletal System	Arthritis | Osteoarthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.96940127 %)	Approved, Vet approved	27742486
DrugRepV_2413	Entacapone	Nervous System	Parkinson Disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.96747673 %)	Approved	27742486
DrugRepV_2414	Flunarizine Dihydrochloride	Nervous System	Migraine | Vertigo | Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.96747673 %)	Approved	27742486
DrugRepV_2415	Adenine Sulfate	NA	Nutritional supplement	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.95953472 %)	Approved	27742486
DrugRepV_2416	Artemisinin	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.94527744 %)	Experimental	27742486
DrugRepV_2417	Mitotane	Antineoplastic and Immunomodulating Agents	Adrenocortical tumours | Cushing's syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.940259 %)	Approved	27742486
DrugRepV_2418	L-Adrenaline	Alimentary Tract And Metabolism; Blood and Blood Forming Organs; Cardiovascular agents; Respiratory	Allergic reactions (including anaphylaxis)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.93700765 %)	Approved, Vet approved	27742486
DrugRepV_2419	Ranolazine	Cardiovascular agents	Chronic angina | Ventricular tachycardia | Acute coronary syndrome | Microvascular coronary dysfunction | Arrhythmia | Glycemic control	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.92187432 %)	Approved, Investigational	27742486
DrugRepV_2420	Altretamine	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.89361145 %)	Approved	27742486
DrugRepV_2421	Manidipine	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.86580948 %)	Approved, Investigational	27742486
DrugRepV_2422	Imiquimod	Dermatologicals	Genital and perianal warts/condyloma acuminata	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.85929889 %)	Approved, Investigational	27742486
DrugRepV_2423	Vardenafil	Genito Urinary System and Sex Hormones	Erectile dysfunction	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.82388881 %)	Approved	27742486
DrugRepV_2424	Sulfameter	Antiinfectives For Systemic Use	Leprosy | Urinary | Respiratory tract infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.81863222 %)	Approved	27742486
DrugRepV_2425	Quinapril Hydrochloride	Cardiovascular agents	Hypertension | Congestive heart failure	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.78829028 %)	Approved, Investigational	27742486
DrugRepV_2426	Norfloxacin	Antiinfectives For Systemic Use	Urinary tract infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.69457675 %)	Approved	27742486
DrugRepV_2427	Chlorprothixene	Nervous System	Psychosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.68794785 %)	Approved	27742486
DrugRepV_2428	L-Glutamine	Alimentary Tract and Metabolism	Nutritional supplementation | Sickle cell disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.67790051 %)	Approved, Investigational, Nutraceutical	27742486
DrugRepV_2429	Fluvoxamine Maleate	Nervous System	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.66473263 %)	Approved, Investigational	27742486
DrugRepV_2430	Sulindac	Musculo-Skeletal System	Osteoarthritis | Rheumatoid arthritis | Ankylosing spondylitis | Acute painful shoulder | Acute gouty arthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.66082495 %)	Approved, Investigational	27742486
DrugRepV_2431	Mitiglinide Calcium	Alimentary Tract and Metabolism	Type 2 diabetes	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.63590267 %)	Investigational	27742486
DrugRepV_2432	Trazodone Hydrochloride	Nervous System	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.62662677 %)	Approved, Investigational	27742486
DrugRepV_2433	Rocuronium Bromide	Musculo-Skeletal System	Muscle fasciculation caused by succinylcholine	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.57246722 %)	Approved	27742486
DrugRepV_2434	Sarafloxacin Hydrochloride	Antibacterial	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.52020966 %)	Vet approved, Withdrawn	27742486
DrugRepV_2435	Sulfadoxine	Antiparasitic	Malaria	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.46534855 %)	Approved, Investigational	27742486
DrugRepV_2436	Lomustine	Antineoplastic and Immunomodulating Agents	Brain tumor	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.46226348 %)	Approved, Investigational	27742486
DrugRepV_2437	Silodosin	Genito Urinary System and Sex Hormones	Prostatic hyperplasia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.43672555 %)	Approved	27742486
DrugRepV_2438	Rimantadine	Antiinfectives For Systemic Use	Influenza A virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.43192971 %)	Approved, Investigational	27742486
DrugRepV_2439	Rifapentine	Antiinfectives For Systemic Use	Tuberculosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.3653391 %)	Approved, Investigational	27742486
DrugRepV_2440	Racecadotril	Antibacterial	Diarrhea | Acute Diarrhea | Acute Gastroenteritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.33496745 %)	Investigational	27742486
DrugRepV_2441	Zoledronic Acid	Musculo-Skeletal System	Hypercalcemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.32603653 %)	Approved	27742486
DrugRepV_2442	Granisetron Hydrochloride	Alimentary Tract and Metabolism	Nausea | Vomiting	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.32603653 %)	Approved, Investigational	27742486
DrugRepV_2443	Betamethasone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Edocrine disorders, rheumatic disorders, collagen diseases	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.2771865 %)	Approved	27742486
DrugRepV_2444	Pamidronate Disodium	Musculo-Skeletal System	Hypercalcemia associated with malignancy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.23979587 %)	Approved	27742486
DrugRepV_2445	Gatifloxacin	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, sinusitis, Community-acquired pneumonia, and Skin infections)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.22310404 %)	Approved, Investigational	27742486
DrugRepV_2446	Moexipril Hydrochloride	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.15869259 %)	Approved	27742486
DrugRepV_2447	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.14736269 %)	Approved	27742486
DrugRepV_2448	Cefoperazone	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.13001149 %)	Approved	27742486
DrugRepV_2449	Tetracycline Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections (Rocky Mountain spotted fever | Typhus fever | Tick fevers | Q fever | Rickettsialpox | Brill-Zinsser disease)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.08422039 %)	Approved, Vet approved	27742486
DrugRepV_2450	Gemcitabine Hydrochloride	Antineoplastic and Immunomodulating Agents	Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.05561841 %)	Approved	27742486
DrugRepV_2451	Bifonazole	Dermatologicals	Fungal infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.03205443 %)	Approved	27742486
DrugRepV_2452	Bisoprolol	Cardiovascular agents	Cardiovascular disease, angina pectoris and myocardial infarction	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.01316496 %)	Approved	27742486
DrugRepV_2453	Rosiglitazone Maleate	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.00342918 %)	Approved, Investigational	27742486
DrugRepV_2454	Ondansetron Hydrochloride	Alimentary Tract and Metabolism	Nausea | Vomiting	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.99825786 %)	Approved	27742486
DrugRepV_2455	Sulphadimethoxine	Antiinfectives For Systemic Use	Respiratory infection | Urinary tract infection | Enteric infection | Soft tissue infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.99278461 %)	Approved, Vet approved	27742486
DrugRepV_2456	Masitinib	Antineoplastic and Immunomodulating Agents	Mast cell tumors in dogs	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.95794841 %)	Investigational, Vet approved	27742486
DrugRepV_2457	Amikacin Hydrate	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.87227544 %)	Approved	27742486
DrugRepV_2458	Acyclovir	Dermatologicals; Antiinfectives For Systemic Use; Sensory Organ	Viral infections (Herpes simplex, Zoster and varicella zoster)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.8679278 %)	Approved	27742486
DrugRepV_2459	Pyrazinamide	Antiinfectives For Systemic Use	Tuberculosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.85917346 %)	Approved, Investigational	27742486
DrugRepV_2460	Triamcinolone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Allergic rhinitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.85708189 %)	Approved	27742486
DrugRepV_2461	Tenoxicam	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Backache | Pain	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.85680778 %)	Approved	27742486
DrugRepV_2462	Propafenone	Cardiovascular agents	Arrhythmia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.83756587 %)	Approved	27742486
DrugRepV_2463	Dexamethasone Acetate	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Dermatologicals; Systemic H	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.81918681 %)	Approved	27742486
DrugRepV_2464	Megestrol Acetate	Genito Urinary System and Sex Hormones	Anorexia | Cachexia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.80324191 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2465	Sodium Butyrate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.80232337 %)	NA	27742486
DrugRepV_2466	Mometasone Furoate	Dermatologicals and Respiratory System	Asthma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.77748045 %)	Approved, Vet approved	27742486
DrugRepV_2467	Xylometazoline Hydrochloride	Respiratory System; Sensory Organ	Nasal congestion and minor inflammation due to allergies or colds	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.77290647 %)	Approved	27742486
DrugRepV_2468	Gestodene	Genito Urinary System and Sex Hormones	Progestogen hormonal contraceptive	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.76107127 %)	Investigational	27742486
DrugRepV_2469	Milrinone	Cardiovascular agents	Cardiotonic agent	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.70603205 %)	Approved	27742486
DrugRepV_2470	Cilnidipine	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.67413581 %)	Approved	27742486
DrugRepV_2471	Azelnidipine	NA	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.64469838 %)	Approved	27742486
DrugRepV_2472	Anagrelide Hydrochloride	Antineoplastic and Immunomodulating Agents	Thrombocytosis and chronic myeloid leukemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.62449045 %)	Approved	27742486
DrugRepV_2473	Levonorgestrel	Genito Urinary System and Sex Hormones	Menopausal and postmenopausal disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.60239654 %)	Approved, Investigational	27742486
DrugRepV_2474	Sulfisoxazole	Antiinfectives For Systemic Use; Sensory Organ	Urinary tract infections | Meningococcal meningitis | Acute otitis media | Trachoma | Inclusion conjunctivitis | Nocardiosis | Chancroid | Toxoplasmosis | Malaria	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.58656517 %)	Approved, Vet approved	27742486
DrugRepV_2475	Acadesine	Cardiovascular agents	Cardiac reperfusion injury, cardiovascular disorders, and coronary artery disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.50184624 %)	Approved	27742486
DrugRepV_2476	Ethionamide	Antiinfectives For Systemic Use	Tuberculosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.45109184 %)	Approved	27742486
DrugRepV_2477	Mestranol	NA	Contraception	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.44756785 %)	Approved	27742486
DrugRepV_2478	Streptomycin Sulfate	Antiinfectives For Systemic Use	Tuberculosis | Tularemia | Plague | Brucellosis | Endocarditis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.42772783 %)	Approved, Vet approved	27742486
DrugRepV_2479	Nizatidine	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) | Peptic ulcer disease | Active benign gastric ulcer | Active duodenal ulcer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.40022928 %)	Approved	27742486
DrugRepV_2480	Vidarabine	Antiinfectives For Systemic Use; Sensory Organ	Viral infections (Chickenpox, Herpes simplex, Zoster and varicella zoster)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.36868435 %)	Approved	27742486
DrugRepV_2481	Dopamine Hydrochloride	Cardiovascular agents	Arrythmias and arterial hypotension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.35461971 %)	Approved	27742486
DrugRepV_2482	Butoconazole Nitrate	Genito Urinary System and Sex Hormones	Vulvovaginal candidiasis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.33976627 %)	Approved	27742486
DrugRepV_2483	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.33541797 %)	Approved	27742486
DrugRepV_2484	Dacarbazine	Antineoplastic and Immunomodulating Agents	Hodgkin disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.32719355 %)	Approved	27742486
DrugRepV_2485	Genistein	Antihelmintic	Prostate cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.32554274 %)	Investigational	27742486
DrugRepV_2486	Cefditoren Pivoxil	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.31336219 %)	Approved	27742486
DrugRepV_2487	Esomeprazole Sodium	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.29986636 %)	Approved	27742486
DrugRepV_2488	Aspartame	NA	Diet supplement and sugar substitute	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.28008959 %)	Approved	27742486
DrugRepV_2489	Amfebutamone	Nervous System	Depression	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.27113824 %)	Approved	27742486
DrugRepV_2490	Risedronate Sodium	Musculo-Skeletal System	Paget's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.24157209 %)	Approved, Investigational	27742486
DrugRepV_2491	Guaifenesin	Respiratory System	Cold | Bronchitis or other breathing illnesses	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.24064615 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2492	Dexrazoxane Hydrochloride	Various	Cardiomyopathy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.23802475 %)	Approved	27742486
DrugRepV_2493	Scopine	Alimentary Tract And Metabolism; Nervous System; Sensory Organ	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.22869183 %)	NA	27742486
DrugRepV_2494	Curcumin	NA	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.21930657 %)	Approved	27742486
DrugRepV_2495	Ramelteon	Nervous System	Insomnia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.19581857 %)	Approved, Investigational	27742486
DrugRepV_2496	Deflazacort	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Duchenne muscular dystrophy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.19023033 %)	Approved	27742486
DrugRepV_2497	Procarbazine Hydrochloride	Antineoplastic and Immunomodulating Agents	Hodgkin's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.16145424 %)	Approved	27742486
DrugRepV_2498	Cephalomannine	Antineoplastic	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.14550814 %)	NA	27742486
DrugRepV_2499	Donepezil Hydrochloride	Nervous System	Dementia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.11302961 %)	Approved	27742486
DrugRepV_2500	Olmesartan Medoxomil	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.09317819 %)	Approved, Investigational	27742486
DrugRepV_2501	Disodium Cromoglycate	Alimentary Tract And Metabolism; Dermatologicals; Respiratory System; Respiratory System; Sensory Or	Allergy and asthma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.0865219 %)	Approved	27742486
DrugRepV_2502	Meglumine	Antiparasitic products, Insectisides and Repellents	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.08526202 %)	Approved	27742486
DrugRepV_2503	Isoprenaline Hydrochloride	Cardiovascular agents	Heart block	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.06631438 %)	Approved, Investigational	27742486
DrugRepV_2504	Tizanidine Hydrochloride	Musculo-Skeletal System	Muscle spasms | Multiple sclerosis | Stroke | Acquired brain injury or a Spinal cord injury	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.04828156 %)	Approved, Investigational	27742486
DrugRepV_2505	Dofetilide	Cardiovascular agents	Arrhythmia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.03153927 %)	Approved	27742486
DrugRepV_2506	Nelarabine	Antineoplastic and Immunomodulating Agents	T-cell acute lymphoblastic leukemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.02495853 %)	Approved, Investigational	27742486
DrugRepV_2507	L-Arginine Hydrochloride	Blood and Blood Forming Organs	Nutritional supplementation	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.02074722 %)	Investigational, Nutraceutical	27742486
DrugRepV_2508	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Decrease (100 %)	Approved	27742486
DrugRepV_2509	Niflumic Acid	Musculo-Skeletal System	Rheumatoid arthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Decrease (100 %)	Approved	27742486
DrugRepV_2510	Maraviroc	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.0137712 %)	Approved, Investigational	27742486
DrugRepV_2511	Carbenicillin Disodium	Antiinfectives For Systemic Use	Urinary tract infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.0151285 %)	Approved	27742486
DrugRepV_2512	Tetracaine Hydrochloride	Dermatologicals	Local dermal analgesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.0174276 %)	Approved, Vet approved	27742486
DrugRepV_2513	Methscopolamine	Alimentary Tract And Metabolism; Sensory Organ	Peptic ulcers	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.0240882 %)	Approved	27742486
DrugRepV_2514	Phenindione	Blood and Blood Forming Organs	Cardiomyopathy, atrial fibrillation	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.0791815 %)	Approved, Investigational	27742486
DrugRepV_2515	Talc	NA	Rashes	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.1085991 %)	Approved	27742486
DrugRepV_2516	Ketotifen Fumarate	Respiratory System	Atopic asthma | Conjunctivitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.1370416 %)	Approved	27742486
DrugRepV_2517	Clarithromycin	Antiinfectives For Systemic Use	Microbial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.1486584 %)	Approved	27742486
DrugRepV_2518	Ganciclovir	Antiinfectives For Systemic Use	Cytomegalovirus infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.183847 %)	Approved, Investigational	27742486
DrugRepV_2519	Rosiglitazone Hydrochloride	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.2146764 %)	Approved	27742486
DrugRepV_2520	Irbesartan	Cardiovascular agents	Hypertension | Diabetic nephropathy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.2498496 %)	Approved, Investigational	27742486
DrugRepV_2521	Pregnenolone	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.2797662 %)	Approved, Experimental	27742486
DrugRepV_2522	Pyridostigmine bromide	Nervous System	Myasthenia gravis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.333684 %)	Approved, Investigational	27742486
DrugRepV_2523	Nadifloxacin	Dermatologicals	Acne Vulgaris	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.3986672 %)	Investigational	27742486
DrugRepV_2524	Gimeracil	Anticancer	Gastric cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.4276036 %)	Approved	27742486
DrugRepV_2525	Altrenogest	Veterinary medicine	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.4278845 %)	Approved, Vet Approved	27742486
DrugRepV_2526	Edaravone	Neurologic-agent	Amyotrophic lateral scleorosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.4295646 %)	Approved	27742486
DrugRepV_2527	Acetylcholine Chloride	Sensory Organ	Ophthalmological Disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.4447588 %)	Approved	27742486
DrugRepV_2528	Artemether	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.4769483 %)	Approved	27742486
DrugRepV_2529	Axitinib	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.5090732 %)	Approved	27742486
DrugRepV_2530	Moxifloxacin Hydrochloride	Antiinfectives For Systemic Use	Sinusitis | Pneumonia | Chronic bronchitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.5365847 %)	Approved, Investigational	27742486
DrugRepV_2531	Meropenem	Antiinfectives For Systemic Use	Bacterial infections (Skin infection)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.5411877 %)	Approved, Investigational	27742486
DrugRepV_2532	Methocarbamol	Musculo-Skeletal System	Muscle spasms	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.5777085 %)	Approved, Vet approved	27742486
DrugRepV_2533	Pimobendan	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.5850328 %)	Vet approved	27742486
DrugRepV_2534	Vandetanib	Antineoplastic and Immunomodulating Agents	Medullary thyroid cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.588259 %)	Approved	27742486
DrugRepV_2535	FK-506	Dermatologicals; Antineoplastic and Immunomodulating Agents	Liver transplantation	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6057741 %)	Approved	27742486
DrugRepV_2536	Paclitaxel	Antineoplastic and Immunomodulating Agents	Kaposi's sarcoma | Lung cancer | Ovarian cancer | Breast cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6093096 %)	Approved	27742486
DrugRepV_2537	Naltrexone Hydrochloride	Nervous System	Alcohol dependence	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6142901 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2538	Alibendol	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6238122 %)	NA	27742486
DrugRepV_2539	Vicriviroc Malate	NA	AIDS	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6325066 %)	Investigational	27742486
DrugRepV_2540	Valacyclovir Hydrochloride	Antiinfectives For Systemic Use	Herpes simplex and Zoster virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6677761 %)	Approved	27742486
DrugRepV_2541	Disulfiram	Nervous System	Chronic alcoholism	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6684287 %)	Approved	27742486
DrugRepV_2542	Sodium orthovanadate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6967088 %)	NA	27742486
DrugRepV_2543	Cefaclor	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.7251215 %)	Approved	27742486
DrugRepV_2544	Tretinoin	Dermatologicals; Antineoplastic and Immunomodulating Agents	Acne | Photodamaged skin | Keratinization disorders such as ichthyosis and keratosis follicularis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.7746726 %)	Approved	27742486
DrugRepV_2545	Irsogladine	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.8011514 %)	Investigational	27742486
DrugRepV_2546	Ciprofloxacin	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.8107955 %)	Approved	27742486
DrugRepV_2547	Orphenadrine Citrate	Musculo-Skeletal System	Parkinson disease and Muscle spasm	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.8107955 %)	Approved	27742486
DrugRepV_2548	Sodium salicylate	Nervous System	Acne | Psoriasis | Callouses | Corns Keratosis pilaris | Warts	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.8129041 %)	Approved	27742486
DrugRepV_2549	Diethylstilbestrol	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.85143 %)	Approved	27742486
DrugRepV_2550	Albendazole	Antiparasitic products, Insectisides and Repellents	Parasitic infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.8595872 %)	Approved	27742486
DrugRepV_2551	Tobramycin	Antiinfectives For Systemic Use; Sensory Organ	Pseudomonas Aeruginosa (Bacteria) lung infections | Sinus infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.8678849 %)	Approved, Investigational	27742486
DrugRepV_2552	Diltiazem Hydrochloride	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.874358 %)	Approved	27742486
DrugRepV_2553	Loteprednol Etabonate	Sensory Organ	Allergic conjunctivitis | Uveitis | Acne rosacea | Superficial punctate keratitis | Herpes zoster keratitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.8962545 %)	Approved	27742486
DrugRepV_2554	Oxytetracycline dihydrate	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.9136131 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2555	Flubendazole	Antiparasitic products, Insectisides and Repellents	Helminthiasis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.9381124 %)	Experimental, Withdrawn	27742486
DrugRepV_2556	Oxybutynin Chloride	Genito Urinary System and Sex Hormones	Overactive bladder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.9623606 %)	Approved, Investigational	27742486
DrugRepV_2557	Aztreonam	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.9905633 %)	Approved	27742486
DrugRepV_2558	Ranitidine	Alimentary Tract and Metabolism	Duodenal ulcer | Pathological hypersecretion of gastric acid | Gastric ulcer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.0007669 %)	Approved	27742486
DrugRepV_2559	Phentolamine Mesilate	Cardiovascular agents	Pheochromocytoma | Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.022123 %)	Approved	27742486
DrugRepV_2560	Cilazapril Monohydrate	Cardiovascular agents	Hypertension and heart failure	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.0262964 %)	Approved	27742486
DrugRepV_2561	Mirtazapine	Nervous System	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.0396288 %)	Approved	27742486
DrugRepV_2562	Docosanol	Dermatologicals	Herpes simplex episodes	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.0813812 %)	Approved	27742486
DrugRepV_2563	Detomidine Hydrochloride	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.086047 %)	Approved, Vet Approved	27742486
DrugRepV_2564	Hydroxyflutamide	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.1400626 %)	NA	27742486
DrugRepV_2565	Ginkgolide A	Plant extract	Inflammatory disorder | immunological disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.1811648 %)	Nutraceutical	27742486
DrugRepV_2566	Lincomycin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.1874718 %)	Approved, Vet approved	27742486
DrugRepV_2567	Pralatrexate	Antineoplastic and Immunomodulating Agents	T-cell lymphoma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.1883229 %)	Approved, Investigational	27742486
DrugRepV_2568	Oxacillin Sodium Monohydrate	Antiinfectives For Systemic Use	Staphylococci infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.2220202 %)	Approved, Investigational	27742486
DrugRepV_2569	Entecavir Hydrate	Antiinfectives For Systemic Use	Hepatitis B virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.2373625 %)	Approved	27742486
DrugRepV_2570	Ursodiol	NA	Gallstone and cholestatic forms of liver diseases including primary biliary cirrhosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.242893 %)	Approved	27742486
DrugRepV_2571	Bendamustine Hydrochloride	Antineoplastic and Immunomodulating Agents	Chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.2429281 %)	Approved	27742486
DrugRepV_2572	Camptothecin	Anticancer	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.2458719 %)	Approved	27742486
DrugRepV_2573	Nimodipine	Cardiovascular agents	Subarachnoid hemorrhage (SAH)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.2547481 %)	Approved, Investigational	27742486
DrugRepV_2574	BIBR-1048	Blood and Blood Forming Organs	Thrombosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.2578913 %)	Approved	27742486
DrugRepV_2575	Amprenavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.2615469 %)	Approved	27742486
DrugRepV_2576	Isradipine	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.2706832 %)	Approved, Investigational	27742486
DrugRepV_2577	Cimetidine	Alimentary Tract and Metabolism	Peptic ulcers, heartburn and acid indigestion	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.3280471 %)	Approved	27742486
DrugRepV_2578	Rosuvastatin Calcium	Cardiovascular agents	Hyperlipidemia | Dyslipidemia | Hypertriglyceridemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.3486114 %)	Approved	27742486
DrugRepV_2579	Chlormezanone	Musculo-Skeletal System	Anxiety and muscle spasm	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.3558347 %)	Approved	27742486
DrugRepV_2580	Quinine Hydrochloride dihydrate	Antiparasitic products, Insectisides and Repellents	Malaria | Leg cramps	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.3590955 %)	Approved	27742486
DrugRepV_2581	Salbutamol Sulfate	Respiratory System	Bronchial asthma | Chronic bronchitis | Chronic bronchopulmonary disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.3636934 %)	Approved, Vet approved	27742486
DrugRepV_2582	Vecuronium bromide	Musculo-Skeletal System	Non-depolarizing neuromuscular blocking agent	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.3726313 %)	Approved	27742486
DrugRepV_2583	Darifenacin Hydrobromide	Genito Urinary System and Sex Hormones	Overactive bladder with symptoms of urge urinary incontinence, urgency and frequency	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.3801387 %)	Approved	27742486
DrugRepV_2584	Flumequine	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.3882128 %)	Withdrawn	27742486
DrugRepV_2585	Dexamethasone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Dermatologicals; Systemic H	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.3910252 %)	Approved	27742486
DrugRepV_2586	Bleomycin Sulfate	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.3921953 %)	Approved	27742486
DrugRepV_2587	Prednisolone Acetate	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Congenital adrenal hyperplasia | Thyroiditis | Psoriatic arthritis | Rheumatoid arthritis | Ankylosing spondylitis | Bursitis | Acute gouty arthritis | Epicondylitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.3985941 %)	Approved, Vet approved	27742486
DrugRepV_2588	Oxybutynin	Genito Urinary System and Sex Hormones	Overactive bladder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.4048985 %)	Approved, Investigational	27742486
DrugRepV_2589	Irinotecan	Antineoplastic and Immunomodulating Agents	Colorectal cancer | Small cell lung cancer | Cervical cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.4109846 %)	Approved, Investigational	27742486
DrugRepV_2590	Sulfasalazine	Alimentary Tract and Metabolism	Inflammatory bowel diseases | Crohn disease | Rheumatoid arthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.4225909 %)	Approved	27742486
DrugRepV_2591	Thalidomide	Antineoplastic and Immunomodulating Agents	Erythema nodosum leprosum	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.433969 %)	Approved, Investigational, Withdrawn	27742486
DrugRepV_2592	Bumetanide	Cardiovascular agents	Edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.4483238 %)	Approved	27742486
DrugRepV_2593	Articaine Hydrochloride	Nervous System	Anaesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.4948978 %)	Approved	27742486
DrugRepV_2594	Vitamin B12	Blood and Blood Forming Organs	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.5062413 %)	Approved	27742486
DrugRepV_2595	Erdosteine	Respiratory System	Chronic bronchitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.5223486 %)	Approved	27742486
DrugRepV_2596	Methacycline Hydrochloride	NA	Acute bacterial exacerbations of chronic bronchitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.5238499 %)	Approved, Investigational	27742486
DrugRepV_2597	Letrozole	Antineoplastic and Immunomodulating Agents	Breast cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.5283999 %)	Approved, Investigational	27742486
DrugRepV_2598	Telbivudine	Antiinfectives For Systemic Use	Hepatitis B virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.5369604 %)	Approved	27742486
DrugRepV_2599	Methyldopa	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.5755527 %)	Approved	27742486
DrugRepV_2600	Betaxolol Hydrochloride	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.5822028 %)	Approved	27742486
DrugRepV_2601	Phenacetin	Nervous System	Analgesic	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.5882537 %)	Withdrawn	27742486
DrugRepV_2602	Topotecan Hydrochloride	Antineoplastic and Immunomodulating Agents	Ovarian cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.5991588 %)	Approved, Investigational	27742486
DrugRepV_2603	Suprofen	Musculo-Skeletal System	Miosis (pupil constriction)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.6028527 %)	Approved, Withdrawn	27742486
DrugRepV_2604	Riboflavin	Alimentary Tract and Metabolism	Vitamin B2 deficiency	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.6151556 %)	Approved, Investigational, Nutraceutical, Vet approved	27742486
DrugRepV_2605	Dapoxetine Hydrochloride	Genito Urinary System and Sex Hormones	Premature ejaculation	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.6280168 %)	Approved	27742486
DrugRepV_2606	Lomefloxacin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections (respiratory tract (chronic bronchitis) and urinary tract)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.6544832 %)	Approved, Investigational	27742486
DrugRepV_2607	Linezolid	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.6567659 %)	Approved, Investigational	27742486
DrugRepV_2608	Exemestane	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.6612547 %)	Approved	27742486
DrugRepV_2609	Nevirapine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.6918978 %)	Approved	27742486
DrugRepV_2610	2-Methoxyestradiol	NA	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7014075 %)	Investigational	27742486
DrugRepV_2611	Felbamate	Nervous System	Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7147317 %)	Approved	27742486
DrugRepV_2612	Felodipine	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7151698 %)	Approved, Investigational	27742486
DrugRepV_2613	Azathioprine	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis, renal transplant rejection, Crohn disease, and colitis.	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.720627 %)	Approved	27742486
DrugRepV_2614	Fludarabine	Antineoplastic and Immunomodulating Agents	Hematological malignancies	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7238787 %)	Approved	27742486
DrugRepV_2615	Zonisamide	Nervous System	Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7356315 %)	Approved	27742486
DrugRepV_2616	Floxuridine	Anticancer	Gastrointestinal adenocarcinomas	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7449704 %)	Approved	27742486
DrugRepV_2617	Cisplatin	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7493506 %)	Approved	27742486
DrugRepV_2618	Benazepril Hydrochloride	Cardiovascular agents	Hypertension, congestive heart failure and chronic renal failure	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7768175 %)	Approved	27742486
DrugRepV_2619	Nafamostat Mesylate	NA	Blood vessel coagulation | Hemorrhagic lesions	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7795584 %)	Investigational	27742486
DrugRepV_2620	Trospium Chloride	Genito Urinary System and Sex Hormones	Overactive bladder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7986713 %)	Approved	27742486
DrugRepV_2621	Propylthiouracil	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hyperthyroidism	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8029587 %)	Approved, Investigational	27742486
DrugRepV_2622	Cilostazol	Blood and Blood Forming Organs	Intermittent claudication	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8044261 %)	Approved	27742486
DrugRepV_2623	Liranaftate	NA	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8068752 %)	NA	27742486
DrugRepV_2624	Scopine Hydrochloride	Alimentary Tract And Metabolism; Nervous System; Sensory Organ	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8166672 %)	Approved, Investigational	27742486
DrugRepV_2625	NAD	NA	Parkinson's disease | Chronic fatigue syndrome | Alzheimer's disease | Cardiovascular disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8213385 %)	Approved	27742486
DrugRepV_2626	Voriconazole	Antiinfectives For Systemic Use	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8244532 %)	Approved	27742486
DrugRepV_2627	Nitrendipine	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8300478 %)	Approved, Investigational	27742486
DrugRepV_2628	Leucovorin calcium	Various	Osteosarcoma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8474034 %)	Approved	27742486
DrugRepV_2629	Vancomycin Hydrochloride	Alimentary Tract And Metabolism; Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8521766 %)	Approved	27742486
DrugRepV_2630	Pantothenic Acid	Alimentary Tract And Metabolism; Dermatologicals	Testicular torsion | Diabetic ulceration | Wound healing | Acne | Obesity | Diabetic peripheral polyneuropathy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8616502 %)	Approved, Nutraceutical, Vet approved	27742486
DrugRepV_2631	Amitriptyline Hydrochloride	Nervous System	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8631848 %)	Approved	27742486
DrugRepV_2632	Balofloxacin	Antibacterial	Bacterial infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.9028632 %)	Approved	27742486
DrugRepV_2633	Zileuton	NA	Asthma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.9379253 %)	Approved, Withdrawn	27742486
DrugRepV_2634	Clopidogrel	Blood and Blood Forming Organs	Myocardial infarction	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.943957 %)	Approved	27742486
DrugRepV_2635	Rebamipide	Alimentary Tract and Metabolism	Stomach Ulcer | Keratoconjunctivitis Sicca | Gastric Adenoma | Early Gastric Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.9454128 %)	Investigational	27742486
DrugRepV_2636	Amiloride Hydrochloride Dihydrate	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.9573532 %)	Approved	27742486
DrugRepV_2637	Valproate Sodium	Nervous System	Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.9922594 %)	Approved	27742486
DrugRepV_2638	Imatinib	Antineoplastic and Immunomodulating Agents	Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.0019627 %)	Approved	27742486
DrugRepV_2639	Gallamine triethiodide	Musculo-Skeletal System	Anesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.0196399 %)	Approved	27742486
DrugRepV_2640	Levofloxacin	Antiinfectives For Systemic Use	Bacterial infections (Conjunctivitis)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.028788 %)	Approved, Investigational	27742486
DrugRepV_2641	Phenoxybenzamine Hydrochloride	Cardiovascular agents	Phaeochromocytoma (malignant) | Benign prostatic hypertrophy | Malignant essential hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.0355134 %)	Approved	27742486
DrugRepV_2642	Cephalexin	Antibiotics	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.0410882 %)	Approved	27742486
DrugRepV_2643	Sumatriptan Succinate	Nervous System	Migraine disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.0465676 %)	Approved, Investigational	27742486
DrugRepV_2644	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.0495258 %)	Approved, Investigational	27742486
DrugRepV_2645	Cidofovir	Antiinfectives For Systemic Use	Cytomegalovirus infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.1015434 %)	Approved	27742486
DrugRepV_2646	Pazopanib Hydrochloride	Antineoplastic and Immunomodulating Agents	Advanced renal cell cancer | Advanced soft tissue sarcoma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.1099434 %)	Approved	27742486
DrugRepV_2647	Esomeprazole Magnesium	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.1210661 %)	Approved	27742486
DrugRepV_2648	Pioglitazone	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.1624894 %)	Approved, Investigational	27742486
DrugRepV_2649	Aminophylline	Respiratory System	Asthma, bronchospasm and Chronic Obstructive Pulmonary Disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.1683375 %)	Approved	27742486
DrugRepV_2650	Bepotastine besilate	NA	Allergic rhinitis and uriticaria/puritus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.1704391 %)	Approved	27742486
DrugRepV_2651	Clafen	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.1776836 %)	Approved	27742486
DrugRepV_2652	Nepafenac	Sensory Organ	Inflammation associated with cataract surgery	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.1896457 %)	Approved	27742486
DrugRepV_2653	Fluconazole	Antiinfectives For Systemic Use	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.2384772 %)	Approved, Investigational	27742486
DrugRepV_2654	Trimethoprim	Antiinfectives For Systemic Use	Urinary tract infections | Uncomplicated pyelonephritis (with sulfamethoxazole) | Mild acute prostatitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.2572502 %)	Approved	27742486
DrugRepV_2655	Dyphylline	Respiratory System	Chronic bronchitis and emphysema	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.2577836 %)	Approved	27742486
DrugRepV_2656	Fludarabine phosphate	Antineoplastic and Immunomodulating Agents	Hematological malignancies	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.2595351 %)	Approved	27742486
DrugRepV_2657	Bimatoprost	Sensory Organ	Ocular Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.2748636 %)	Approved	27742486
DrugRepV_2658	Febuxostat	Musculo-Skeletal System	Hyperuricemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.3323109 %)	Approved	27742486
DrugRepV_2659	Carboplatin	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.3400754 %)	Approved	27742486
DrugRepV_2660	Acarbose	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.3477084 %)	Approved	27742486
DrugRepV_2661	Biotin	Alimentary Tract and Metabolism	Nutritional supplementation	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.3585021 %)	Approved	27742486
DrugRepV_2662	Fluocinonide	Dermatologicals	Eczema	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.3646739 %)	Approved, Investigational	27742486
DrugRepV_2663	Manidipine Dihydrochloride	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.3680473 %)	Approved, Investigational	27742486
DrugRepV_2664	Miglitol	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.380669 %)	Approved	27742486
DrugRepV_2665	Thiabendazole	Dermatologicals; Antiparasitic products, Insectisides and Repellents	Strongyloidiasis (threadworm) | Cutaneous larva migrans (creeping eruption) | Visceral larva migrans | Trichinosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.3865744 %)	Approved	27742486
DrugRepV_2666	Candesartan	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.3946995 %)	Approved	27742486
DrugRepV_2667	Azlocillin Sodium salt	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.4022354 %)	Approved	27742486
DrugRepV_2668	Moguisteine	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.4037393 %)	NA	27742486
DrugRepV_2669	Cetirizine Dihydrochloride	Respiratory System	Allergic rhinitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.4358768 %)	Approved	27742486
DrugRepV_2670	Vincristine	Antineoplastic and Immunomodulating Agents	Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.4398466 %)	Approved	27742486
DrugRepV_2671	Tripelennamine Hydrochloride	Dermatologicals and Respiratory System	Gastrointestinal irritation | Asthma | HAY fever | Urticaria |Rhinitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.4469427 %)	Approved	27742486
DrugRepV_2672	Leflunomide	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.47799 %)	Approved, Investigational	27742486
DrugRepV_2673	Cefprozil Hydrate	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.4845708 %)	Approved	27742486
DrugRepV_2674	Hydralazine Hydrochloride	Cardiovascular agents	Hypertension | Congestive heart failure	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.4875991 %)	Approved	27742486
DrugRepV_2675	Gemfibrozil	Cardiovascular agents	Hyperlipidemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.5184325 %)	Approved	27742486
DrugRepV_2676	Naftifine Hydrochloride	Dermatologicals	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.5283589 %)	Approved	27742486
DrugRepV_2677	Aliskiren Hemifumarate	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.5377825 %)	Approved	27742486
DrugRepV_2678	Amiloride Hydrochloride	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.5420556 %)	Approved	27742486
DrugRepV_2679	Temsirolimus	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.55968 %)	Approved	27742486
DrugRepV_2680	Carbidopa	Neurologic-agent	Parkinson Disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.5784382 %)	Approved	27742486
DrugRepV_2681	Ramipril	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.5841949 %)	Approved	27742486
DrugRepV_2682	Levetiracetam	Nervous System	Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.5916963 %)	Approved, Investigational	27742486
DrugRepV_2683	10-DAB	NA	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.5981982 %)	NA	27742486
DrugRepV_2684	Cladribine	Antineoplastic and Immunomodulating Agents	Lymphoproliferative diseases	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.6030286 %)	Approved	27742486
DrugRepV_2685	Oseltamivir phosphate	Antiinfectives For Systemic Use	Influenza A/B virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.6044621 %)	Approved	27742486
DrugRepV_2686	Estriol	Genito Urinary System and Sex Hormones	Estrogen receptor	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.6485182 %)	Approved	27742486
DrugRepV_2687	Fesoterodine Fumarate	Genito Urinary System and Sex Hormones	Overactive bladder syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.7220164 %)	Approved	27742486
DrugRepV_2688	Chlorpromazine	Nervous System	Schizophrenia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.7555603 %)	Approved	27742486
DrugRepV_2689	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.764086 %)	Approved	27742486
DrugRepV_2690	Capecitabine	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.7889064 %)	Approved	27742486
DrugRepV_2691	Ipratropium bromide	Respiratory System	Asthma | Chronic bronchitis | Emphysema	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.8135236 %)	Approved, Experimental	27742486
DrugRepV_2692	Dextrose	NA	Hypoglycemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.8688015 %)	Approved	27742486
DrugRepV_2693	Cloxacillin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.8753795 %)	Approved	27742486
DrugRepV_2694	Chlorpheniramine Maleate	Respiratory System	Rhinitis, urticaria, allergy, common cold, asthma and hay fever	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.8794966 %)	Approved	27742486
DrugRepV_2695	Atropine	Sensory Organ	Cholinesterase	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.9146303 %)	Approved	27742486
DrugRepV_2696	Nilotinib	Antineoplastic and Immunomodulating Agents	Leukemias | Chronic myeloid leukemia (CML)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.9152275 %)	Approved, Investigational	27742486
DrugRepV_2697	Fleroxacin	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.9243945 %)	Experimental	27742486
DrugRepV_2698	Tolterodine Tartrate	Genito Urinary System and Sex Hormones	Overactive bladder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.9333711 %)	Approved, Investigational	27742486
DrugRepV_2699	Genipin	Plant extract	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.9384281 %)	NA	27742486
DrugRepV_2700	Tenofovir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.9691678 %)	Approved, Investigational	27742486
DrugRepV_2701	Pranoprofen	Sensory Organ	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.9707089 %)	Experimental, Investigational	27742486
DrugRepV_2702	Metronidazole	Antiparasitic products, Insectisides and Repellents	Amebiasis | Vaginitis | Trichomonas infections | Giardiasis | Anaerobic bacteria | Treponemal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.9895213 %)	Approved	27742486
DrugRepV_2703	Dichlorphenamide	Sensory Organ	Glaucoma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.006092 %)	Approved	27742486
DrugRepV_2704	Sulbactam Sodium	Antiinfectives For Systemic Use	Bacterial infections (Skin infection)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.0092385 %)	Approved	27742486
DrugRepV_2705	Tioxolone	Dermatologicals	Seborrhea or Seborrheic dermatitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.0190059 %)	Experimental	27742486
DrugRepV_2706	Sulfadiazine	Antiinfectives For Systemic Use	Rheumatic fever | Meningococcal meningitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.0259808 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2707	Vinblastine	Antineoplastic and Immunomodulating Agents	Cancer (Hodgkin lymphoma | Non-Hodgkin's lymphoma |Testicular | Breast | Lung (Non-small cell lung cancer) | Head and neck | Bladder cancers | Melanoma | Soft tissue sarcoma |Kaposi's sarcoma | Mycosis fungoides (t-cell lymphoma) | Choriocarcinoma)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.0262855 %)	Approved	27742486
DrugRepV_2708	Lisinopril	Cardiovascular agents	Hypertension | Congestive heart failure	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.0316803 %)	Approved, Investigational	27742486
DrugRepV_2709	Arecoline	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.0469253 %)	Experimental	27742486
DrugRepV_2710	D-Cycloserine	Antiinfectives For Systemic Use	Antibiotic	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.0661555 %)	Approved	27742486
DrugRepV_2711	Enalapril Maleate	Cardiovascular agents	Hypertension and Diabetic nephropathies	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.1210281 %)	Approved	27742486
DrugRepV_2712	(R)-Baclofen	Musculo-Skeletal System	Spasticity in multiple sclerosis, autism spectrum disorder, and social withdrawal in fragile X syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.1299275 %)	Approved	27742486
DrugRepV_2713	Perindopril erbumine	Cardiovascular agents	Hypertension | Congestive heart failure	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.1490604 %)	Approved	27742486
DrugRepV_2714	Nicotinamide	Alimentary Tract and Metabolism	Dietary supplement	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.2083988 %)	Approved, Investigational	27742486
DrugRepV_2715	Indacaterol Maleate	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.2126007 %)	Approved	27742486
DrugRepV_2716	Abiraterone Acetate	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.222047 %)	Approved	27742486
DrugRepV_2717	Prasugrel	Blood and Blood Forming Organs	Acute coronary syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.2301485 %)	Approved	27742486
DrugRepV_2718	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma | Renal cell carcinoma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.2495137 %)	Approved, Investigational	27742486
DrugRepV_2719	Lacidipine	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.2613206 %)	Approved, Investigational	27742486
DrugRepV_2720	Tenofovir disoproxil Fumarate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.295385 %)	Approved, Investigational	27742486
DrugRepV_2721	Adefovir dipivoxil	Antiinfectives For Systemic Use	Hepatitis B virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.3056399 %)	Approved	27742486
DrugRepV_2722	Besifloxacin Hydrochloride	Sensory Organ	Bacterial conjunctivitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.332664 %)	Approved	27742486
DrugRepV_2723	Gemcitabine	Antineoplastic and Immunomodulating Agents	Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.356697 %)	Approved	27742486
DrugRepV_2724	Octopamine Hydrochloride	Cardiovascular agents	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.3569036 %)	NA	27742486
DrugRepV_2725	Sildenafil Citrate	Genito Urinary System and Sex Hormones	Erectile dysfunction	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.4050275 %)	Approved, Investigational	27742486
DrugRepV_2726	Saxagliptin	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.414562 %)	Approved	27742486
DrugRepV_2727	Ofloxacin	Antiinfectives For Systemic Use	Respiratory tract infections | Kidney infection | Skin infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.4146475 %)	Approved	27742486
DrugRepV_2728	Pravastatin Sodium	Cardiovascular agents	Hypercholesterolemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.4229682 %)	Approved	27742486
DrugRepV_2729	Creatinine	Neurologic-agent	Amyotrophic Lateral Sclerosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.4231528 %)	Investigational	27742486
DrugRepV_2730	Amlodipine Besylate	Cardiovascular agents	Hypertension and chronic stable angina	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.4244387 %)	Approved	27742486
DrugRepV_2731	Rifabutin	Antiinfectives For Systemic Use	Mycobacterium avium complex (MAC) disease in patients with advanced Acquired immunodeficiency syndrome infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.4674544 %)	Approved, Investigational	27742486
DrugRepV_2732	Adrucil	Antineoplastic and Immunomodulating Agents	Multiple actinic or solar keratoses	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.4729205 %)	Approved	27742486
DrugRepV_2733	Phenytoin Sodium	Nervous System	Seizures	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.4867115 %)	Approved, Vet approved	27742486
DrugRepV_2734	Sulbactam	Antiinfectives For Systemic Use	Bacterial infections (Skin infection)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.5031618 %)	Approved	27742486
DrugRepV_2735	Ivabradine Hydrochloride	Cardiovascular agents	Angina pectoralis | Chronic heart failure	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.5395934 %)	Approved	27742486
DrugRepV_2736	Benserazide	Neurologic-agent	Parkinson's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.5576471 %)	Approved	27742486
DrugRepV_2737	Didanosine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.5849038 %)	Approved	27742486
DrugRepV_2738	Fenbendazole	Antiparasitic products, Insectisides and Repellents	Helminthiasis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.5894807 %)	Vet approved	27742486
DrugRepV_2739	Hygromycin B	Antibacterial	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.6080755 %)	Vet approved	27742486
DrugRepV_2740	Gabapentin Hydrochloride	Nervous System	Epilepsy (seizure)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.614607 %)	Approved	27742486
DrugRepV_2741	Natamycin	Alimentary Tract And Metabolism; Dermatologicals; Genito Urinary System; Sex Hormones; Antiinfective	Fungal blepharitis | Conjunctivitis | Keratitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.6362172 %)	Approved	27742486
DrugRepV_2742	Carbamazepine	Nervous System	Epilepsy and pain	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.6723227 %)	Approved	27742486
DrugRepV_2743	Oxytetracycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.6733944 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2744	Amantadine Hydrochloride	Nervous System	Influenza and Parkinson Disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.6791464 %)	Approved	27742486
DrugRepV_2745	Aripiprazole	Nervous System	Schizophrenia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.7508746 %)	Approved	27742486
DrugRepV_2746	Gabexate Mesylate	NA	Cancer | Ischemia-reperfusion injury | Pancreatitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.7539063 %)	Investigational	27742486
DrugRepV_2747	Rivastigmine Tartrate	Nervous System	Dementia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.7832229 %)	Approved, Investigational	27742486
DrugRepV_2748	Dronedarone Hydrochloride	Cardiovascular agents	Arrhythmia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.8605968 %)	Approved	27742486
DrugRepV_2749	Gabapentin	Nervous System	Epilepsy (seizure)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.8662068 %)	Approved	27742486
DrugRepV_2750	Bupivacaine Hydrochloride	Nervous System	Anesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.8793995 %)	Approved	27742486
DrugRepV_2751	Marbofloxacin	NA	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.8874309 %)	Vet approved	27742486
DrugRepV_2752	Rolipram	Antidepressant	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.9578731 %)	Experimental	27742486
DrugRepV_2753	Telmisartan	Cardiovascular agents	Hypertension | Type 2 diabetes mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.9984663 %)	Approved, Investigational	27742486
DrugRepV_2754	Mesalamine	Alimentary Tract and Metabolism	Ulcerative colitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.0005942 %)	Approved	27742486
DrugRepV_2755	Cortisone Acetate	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Allergies, skin problems, asthma and arthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.0138374 %)	Approved	27742486
DrugRepV_2756	Triamcinolone Acetonide	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Allergic rhinitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.0201161 %)	Approved, Vet approved	27742486
DrugRepV_2757	Risperidone	Nervous System	Schizophrenia | Mood disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.0706996 %)	Approved, Investigational	27742486
DrugRepV_2758	Mercaptopurine	Antineoplastic and Immunomodulating Agents	Acute lymphatic leukemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.11069 %)	Approved	27742486
DrugRepV_2759	Tiotropium Bromide Hydrate	Respiratory System	Chronic obstructive pulmonary disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.1287058 %)	Approved	27742486
DrugRepV_2760	Streptozotocin	Antineoplastic and Immunomodulating Agents	Malignant neoplasms of pancreas (metastatic islet cell carcinoma)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.1556333 %)	Approved, Investigational	27742486
DrugRepV_2761	Glimepiride	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.1556333 %)	Approved	27742486
DrugRepV_2762	Diclofenac	Dermatologicals; Musculo-Skeletal System and Sensory Organ	Fever and pain	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.1617635 %)	Approved	27742486
DrugRepV_2763	Taurine	NA	Nutritional supplementation	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.1985759 %)	Approved	27742486
DrugRepV_2764	Zalcitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.2270809 %)	Approved	27742486
DrugRepV_2765	Tebipenem pivoxil	Antibacterial	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.2767522 %)	NA	27742486
DrugRepV_2766	Rufinamide	Nervous System	Seizure disorder :- Lennox-Gastuat syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.2854179 %)	Approved	27742486
DrugRepV_2767	Oxaliplatin	Antineoplastic and Immunomodulating Agents	Colon Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.2965612 %)	Approved, Investigational	27742486
DrugRepV_2768	Alfacalcidol	Alimentary Tract and Metabolism	Hyperparathyroidism, Hypocalcemia and Osteodystropy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.3172474 %)	Approved	27742486
DrugRepV_2769	Triflusal	Blood and Blood Forming Organs	Thromboembolic disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.3917465 %)	Approved, Investigational	27742486
DrugRepV_2770	Ulipristal	Genito Urinary System and Sex Hormones	Emergency contraceptive and uterine fibroids	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.4064062 %)	Approved	27742486
DrugRepV_2771	Methazolastone	Antineoplastic and Immunomodulating Agents	Refractory anaplastic astrocytoma | Glioblastoma multiforme	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.4157601 %)	Approved, Investigational	27742486
DrugRepV_2772	Progesterone	Genito Urinary System and Sex Hormones	Infertility	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.4329417 %)	Approved, Vet approved	27742486
DrugRepV_2773	Agomelatine	Nervous System	Depression	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.435983 %)	Approved	27742486
DrugRepV_2774	Droxidopa	Cardiovascular agents	Parkinson's Disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.4482179 %)	Approved	27742486
DrugRepV_2775	Flucytosine	Antiinfectives For Systemic Use	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.4557163 %)	Approved, Investigational	27742486
DrugRepV_2776	Ethinyl estradiol	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.4808177 %)	Approved	27742486
DrugRepV_2777	Sulfamerazine	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, prostatitis and urinary tract infections)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.4815833 %)	Approved, Vet approved	27742486
DrugRepV_2778	Ketorolac	Musculo-Skeletal System	Osteoarthritis | Severe Pain	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.5175573 %)	Approved	27742486
DrugRepV_2779	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.5278588 %)	Approved, Investigational	27742486
DrugRepV_2780	BIBR 953	NA	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.5344416 %)	Approved	27742486
DrugRepV_2781	Betahistine Dihydrochloride	Nervous System	Vertigo assosicated with Ménière's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.5509946 %)	Approved	27742486
DrugRepV_2782	Catharanthine	Plant Component	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.560762 %)	NA	27742486
DrugRepV_2783	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.5754617 %)	Approved	27742486
DrugRepV_2784	Naftopidil	Urologic-agent	Urinary Stent	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.5810603 %)	Investigational	27742486
DrugRepV_2785	Bethanechol chloride	Nervous System	Neurogenic bladder dysfunction	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.6656964 %)	Approved	27742486
DrugRepV_2786	Indapamide	Cardiovascular agents	Hypertension | Edema	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.6882509 %)	Approved	27742486
DrugRepV_2787	DL-Adrenaline	Alimentary Tract And Metabolism; Blood and Blood Forming Organs; Cardiovascular agents; Respiratory	Allergic reactions	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.6935822 %)	Approved	27742486
DrugRepV_2788	Tolbutamide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.6951294 %)	Approved, Investigational	27742486
DrugRepV_2789	Linagliptin	Alimentary Tract and Metabolism	Type 2 diabetes mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.7159637 %)	Approved	27742486
DrugRepV_2790	Flurbiprofen	Musculo-Skeletal System	Rheumatoid arthritis | Osteorarthritis | Anklosing spondylitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.7319021 %)	Approved, Investigational	27742486
DrugRepV_2791	Abacavir Sulfate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.7456882 %)	Approved	27742486
DrugRepV_2792	Amlodipine	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.7826838 %)	Approved	27742486
DrugRepV_2793	Tazarotene	Dermatologicals	Psoriasis, acne and sun damaged skin	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.7953339 %)	Approved	27742486
DrugRepV_2794	Torsemide	Cardiovascular agents	Edema and hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.8209892 %)	Approved	27742486
DrugRepV_2795	Roxithromycin	Antiinfectives For Systemic Use	Respiratory tract | Urinary and soft tissue infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.8220241 %)	Approved	27742486
DrugRepV_2796	Ibuprofen lysine	Musculo-Skeletal System	Rheumatoid arthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.8737995 %)	Approved	27742486
DrugRepV_2797	Ondansetron	Alimentary Tract and Metabolism	Nausea | Vomiting	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.9010506 %)	Approved	27742486
DrugRepV_2798	Azacitidine	Antineoplastic and Immunomodulating Agents	French-American-British myelodysplastic syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.9388504 %)	Approved	27742486
DrugRepV_2799	Prilocaine	Nervous System	Anesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.9717216 %)	Approved	27742486
DrugRepV_2800	Octocrylene	Dermatologicals	Sunburn	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.009058 %)	Approved	27742486
DrugRepV_2801	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.0142414 %)	Approved	27742486
DrugRepV_2802	Idarubicin Hydrochloride	Antineoplastic and Immunomodulating Agents	Acute myeloid leukemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.0284839 %)	Approved	27742486
DrugRepV_2803	Maprotiline Hydrochloride	Nervous System	Bipolar depression	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.0613707 %)	Approved, Investigational	27742486
DrugRepV_2804	Rasagiline Mesylate	Nervous System	Idiopathic Parkinson's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.0889023 %)	Approved	27742486
DrugRepV_2805	Plerixafor octahydrochloride	Antineoplastic and Immunomodulating Agents	Mobilization of hematopoietic stem cells	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.1063153 %)	Approved	27742486
DrugRepV_2806	Docetaxel	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.1241227 %)	Approved	27742486
DrugRepV_2807	Varenicline tartrate	Nervous System	Nicotine dependence	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.1953001 %)	Approved	27742486
DrugRepV_2808	Metolazone	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.2375608 %)	Approved	27742486
DrugRepV_2809	Domperidone	Alimentary Tract and Metabolism	Dyspepsia, heartburn, epigastric pain	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.2614756 %)	Approved	27742486
DrugRepV_2810	Amorolfine Hydrochloride	Dermatologicals	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.3091551 %)	Approved	27742486
DrugRepV_2811	Cefoselis Sulfate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.3205301 %)	NA	27742486
DrugRepV_2812	Piroxicam	Musculo-Skeletal System	Osteoarthritis | Rheumatoid arthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.3800641 %)	Approved, Investigational	27742486
DrugRepV_2813	Rizatriptan Benzoate	NA	Migraine disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.3908172 %)	Approved	27742486
DrugRepV_2814	2-Thiouracil	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.4015713 %)	NA	27742486
DrugRepV_2815	Naloxone Hydrochloride	Alimentary Tract And Metabolism; Various	Narcotic depression	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.4307358 %)	Approved, Vet approved	27742486
DrugRepV_2816	Clofarabine	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.4343488 %)	Approved	27742486
DrugRepV_2817	Pimecrolimus	Dermatologicals	Atopic dermatitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.4573493 %)	Approved, Investigational	27742486
DrugRepV_2818	Suplatast tosylate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.4609451 %)	NA	27742486
DrugRepV_2819	Vitamin C	Alimentary Tract and Metabolism	Vitamin C deficiency, scurvy, delayed wound and bone healing, urine acidification	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.5679794 %)	Approved	27742486
DrugRepV_2820	Oxcarbazepine	Nervous System	Partial seizures	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.5907524 %)	Approved	27742486
DrugRepV_2821	Pramipexole Dihydrochloride Monohydrate	Nervous System	Parkinson's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.5989777 %)	Approved, Investigational	27742486
DrugRepV_2822	Naphazoline Hydrochloride	Respiratory System; Sensory Organ	Eyedrops for ocular vasoconstriction or as a nasal preparation for nasal congestion	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.636873 %)	Approved, Investigational	27742486
DrugRepV_2823	Nifedipine	Cardiovascular agents	Vasospastic angina | Chronic stable angina | Hypertension | Raynaud's phenomenon	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.6404656 %)	Approved	27742486
DrugRepV_2824	Cabazitaxel	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.6935891 %)	Approved	27742486
DrugRepV_2825	Nystatin	Alimentary Tract And Metabolism; Dermatologicals	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.7305272 %)	Approved	27742486
DrugRepV_2826	Medetomidine Hydrochloride	Nervous System	Surgical anesthetic | Analgesic	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.7627474 %)	Approved, Vet approved	27742486
DrugRepV_2827	Acetylcysteine	Respiratory System; Sensory Organ; Various	Acetaminophen poisoning	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.8964245 %)	Approved	27742486
DrugRepV_2828	Paroxetine Hydrochloride	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.9168009 %)	Approved, Investigational	27742486
DrugRepV_2829	Mesna	Respiratory System; Various	Hemorrhagic cystitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.9168504 %)	Approved, Investigational	27742486
DrugRepV_2830	Idebenone	Nervous System	Visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.92252 %)	Approved, Investigational	27742486
DrugRepV_2831	Xylazine Hydrochloride	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.9275587 %)	Approved, Vet Approved	27742486
DrugRepV_2832	Ornidazole	Antiparasitic products, Insectisides and Repellents	Elective Colorectal Surgery	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.9457143 %)	Investigational	27742486
DrugRepV_2833	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.947872 %)	Approved	27742486
DrugRepV_2834	Evista	Genito Urinary System and Sex Hormones	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.9810114 %)	Approved	27742486
DrugRepV_2835	Tadalafil	Genito Urinary System and Sex Hormones	Erectile dysfunction	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.0935254 %)	Approved	27742486
DrugRepV_2836	Ezetimibe	Cardiovascular agents	Hyperlipidemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.124775 %)	Approved	27742486
DrugRepV_2837	Pazopanib	Antineoplastic and Immunomodulating Agents	Advanced renal cell cancer | Advanced soft tissue sarcoma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.2172761 %)	Approved	27742486
DrugRepV_2838	Romidepsin	Antineoplastic and Immunomodulating Agents	T-cell lymphoma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.2173849 %)	Approved, Investigational	27742486
DrugRepV_2839	Emtricitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.2439742 %)	Approved	27742486
DrugRepV_2840	Valsartan	Cardiovascular agents	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.2598292 %)	Approved	27742486
DrugRepV_2841	Venlafaxine	Nervous System	Depression | General anxiety disorder | Social phobia | Panic disorder | vasomotor symptoms	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.3017038 %)	Approved	27742486
DrugRepV_2842	Abitrexate	Antineoplastic and Immunomodulating Agents	Gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole and acute lymphocytic leukemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.3272062 %)	Approved	27742486
DrugRepV_2843	Danofloxacin Mesylate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.3487008 %)	Experimental, Vet approved	27742486
DrugRepV_2844	Eplerenone	Cardiovascular agents	Left ventricular systolic dysfunction	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.3670777 %)	Approved	27742486
DrugRepV_2845	Atracurium Besylate	Musculo-Skeletal System	Endotracheal intubation	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.50194 %)	Approved	27742486
DrugRepV_2846	Divalproex Sodium	Nervous System	Seizures	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.5343075 %)	Approved	27742486
DrugRepV_2847	Topiramate	Nervous System	Seizures (Epilepsy) | Migraine	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.553453 %)	Approved	27742486
DrugRepV_2848	Glipizide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.5735462 %)	Approved, Investigational	27742486
DrugRepV_2849	Amikacin Sulfate	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.6506378 %)	Approved	27742486
DrugRepV_2850	Palonosetron Hydrochloride	Alimentary Tract and Metabolism	Nausea and vomiting associated with cancer chemotherapy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.7579581 %)	Approved, Investigational	27742486
DrugRepV_2851	Sulfamethoxazole	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, prostatitis and urinary tract infections)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.7837639 %)	Approved	27742486
DrugRepV_2852	Vildagliptin	Alimentary Tract and Metabolism	Hyperglycemia in type 2 diabetes mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.8331475 %)	Approved	27742486
DrugRepV_2853	Rimonabant	Alimentary Tract and Metabolism	Obesity | Type 2 diabetes or dyslipidaemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.8569753 %)	Approved, Investigational	27742486
DrugRepV_2854	Prednisolone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Congenital adrenal hyperplasia | Thyroiditis | Psoriatic arthritis | Rheumatoid arthritis | Ankylosing spondylitis | Bursitis | Acute gouty arthritis | Epicondylitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.875743 %)	Approved, Vet approved	27742486
DrugRepV_2855	Betamethasone Dipropionate	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Edocrine disorders, rheumatic disorders, collagen diseases	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.8812088 %)	Approved	27742486
DrugRepV_2856	Amidopyrine	NA	Pain	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.8828073 %)	NA	27742486
DrugRepV_2857	Rolipram	Antidepressant	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.8983502 %)	Approved	27742486
DrugRepV_2858	Zolmitriptan	Nervous System	Migraine with or without auras	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.0517546 %)	Approved	27742486
DrugRepV_2859	Ciclopirox ethanolamine	Dermatologicals	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.0876735 %)	Approved	27742486
DrugRepV_2860	Clotrimazole	Dermatologicals	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.1110368 %)	Approved	27742486
DrugRepV_2861	Ubenimex	NA	Acute myelocytic leukemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.1327673 %)	Approved	27742486
DrugRepV_2862	Estradiol	Genito Urinary System and Sex Hormones	Vulvar and vaginal atrophy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.2174786 %)	Approved	27742486
DrugRepV_2863	Pitavastatin Calcium	Cardiovascular agents	Dyslipidemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.2349302 %)	Approved	27742486
DrugRepV_2864	Epirubicin Hydrochloride	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.2856781 %)	Approved	27742486
DrugRepV_2865	Solifenacin Succinate	Genito Urinary System and Sex Hormones	Overactive bladder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.2907234 %)	Approved	27742486
DrugRepV_2866	Carbazochrome Sodium Sulfonate	Blood and Blood Forming Organs	Hemorrhage	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.3048436 %)	Experimental	27742486
DrugRepV_2867	Fexofenadine Hydrochloride	Respiratory System	Allergic rhinitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.3594321 %)	Approved	27742486
DrugRepV_2868	Furosemide	Cardiovascular agents	Edema and Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.3838268 %)	Approved, Vet approved	27742486
DrugRepV_2869	Enrofloxacin	Antibiotics	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.5865927 %)	NA	27742486
DrugRepV_2870	Alverine Citrate	Alimentary Tract and Metabolism	Muscle spasms	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.6069373 %)	Approved	27742486
DrugRepV_2871	Daunorubicin Hydrochloride	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.6172048 %)	Approved	27742486
DrugRepV_2872	Tolvaptan	Cardiovascular agents	Hyponatremia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.7162491 %)	Approved	27742486
DrugRepV_2873	Acitretin	Dermatologicals	Psoriasis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.7772745 %)	Approved	27742486
DrugRepV_2874	Allopurinol	Musculo-Skeletal System	Hyperuricemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.0088421 %)	Approved	27742486
DrugRepV_2875	Peramivir Trihydrate	Antiviral	Influenza A/B virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.0856963 %)	Approved	27742486
DrugRepV_2876	Blonanserin	Neurologic-agent	Schizophrenia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.1057248 %)	Investigational	27742486
DrugRepV_2877	Fenoprofen Calcium Hydrate	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.1318763 %)	Approved	27742486
DrugRepV_2878	Betapar	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.1507562 %)	NA	27742486
DrugRepV_2879	Indomethacin	Cardiovascular agents; Musculo-Skeletal System; Musculo-Skeletal System	Rheumatoid arthritis | Ankylosing spondylitis | Osteoarthritis | Acute painful shoulder (bursitis and/or tendinitis) | Acute gouty arthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.1963187 %)	Approved, Investigational	27742486
DrugRepV_2880	Hydrochlorothiazide	Cardiovascular agents	High blood pressure | Edema	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.2049254 %)	Approved, Vet approved	27742486
DrugRepV_2881	Doxorubicin	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.2310876 %)	Approved	27742486
DrugRepV_2882	Tolnaftate	Dermatologicals	Skin infections (Fungal)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.2646691 %)	Approved	27742486
DrugRepV_2883	Desonide	Dermatologicals	Inflammatory disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.3310624 %)	Approved	27742486
DrugRepV_2884	Aspirin	Alimentary Tract And Metabolism; Blood and Blood Forming Organs; and Nervous System	Rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and ankylosing spondylitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.3358431 %)	Approved	27742486
DrugRepV_2885	Carvedilol	Cardiovascular agents	Congestive heart failure	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.3562769 %)	Approved	27742486
DrugRepV_2886	Stavudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.4649195 %)	Approved, Investigational	27742486
DrugRepV_2887	Melatonin	Nervous System	Jet lag | Insomnia | Shift-work disorder | Circadian rhythm disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.4723795 %)	Approved, Nutraceutical, Vet approved	27742486
DrugRepV_2888	Cinepazide Maleate	Cardiovascular agents	Ischemic Stroke	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.5219495 %)	Investigational	27742486
DrugRepV_2889	Malotilate	NA	Liver disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.5901104 %)	NA	27742486
DrugRepV_2890	Levodopa	Nervous System	Parkinson's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.6262322 %)	Approved	27742486
DrugRepV_2891	PMSF	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.6777643 %)	NA	27742486
DrugRepV_2892	Sparfloxacin	Antiinfectives For Systemic Use	Pneumonia | Acute bacterial exacerbations of chronic bronchitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.7240967 %)	Approved, Investigational, Withdrawn	27742486
DrugRepV_2893	Lurasidone Hydrochloride	Nervous System	Schizophrenia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.7511975 %)	Approved, Investigational	27742486
DrugRepV_2894	Bindarit	Anti-diabetic	Coronary Restenosis and Diabetic Nephropathy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.7514692 %)	Investigational	27742486
DrugRepV_2895	Moclobemide	Nervous System	Depressive disorder | Bipolar disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.9210779 %)	Approved, Investigational	27742486
DrugRepV_2896	Methimazole	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hyperthyroidism | Goiter | Graves disease | Psoriasis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.0110469 %)	Approved	27742486
DrugRepV_2897	Mosapride Citrate	Gastroprokinetic agent	Postoperative Ileus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.0916916 %)	Investigational	27742486
DrugRepV_2898	Ketoprofen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Dysmenorrhea | Pain (sprains and strains, postoperative (including dental surgery) or postpartum pain)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.0969554 %)	Approved, Vet approved	27742486
DrugRepV_2899	Bufexamac	Musculo-Skeletal System	Eczema and dermatoses	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.1032426 %)	Approved	27742486
DrugRepV_2900	Hydrocortisone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Dermatoses | Immune and allergic disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.1034782 %)	Approved, Vet approved	27742486
DrugRepV_2901	Amoxicillin	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.1354562 %)	Approved	27742486
DrugRepV_2902	Cefdinir	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.1747501 %)	Approved	27742486
DrugRepV_2903	Lamotrigine	Nervous System	Epilepsy and bipolar disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.203636 %)	Approved, Investigational	27742486
DrugRepV_2904	Ethisterone	Genito Urinary System and Sex Hormones	Gynecological disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.2262254 %)	NA	27742486
DrugRepV_2905	Rofecoxib	Musculo-Skeletal System	Osteoarthritis | Rheumatoid arthritis | Acute pain in adults | Primary dysmenorrhea | Acute treatment of migraine attacks with or without auras	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.4168988 %)	Approved	27742486
DrugRepV_2906	Sulfathiazole	Dermatologicals; Antiinfectives For Systemic Use	Bacterial infections (Cattle)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.4569269 %)	Approved, Vet approved	27742486
DrugRepV_2907	Tranilast	NA	Bronchial asthma | Keloid and hypertrophic scar | Allergic disorders such as asthma, allergic rhinitis | Atopic dermatitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.5539143 %)	Investigational	27742486
DrugRepV_2908	Aminocaproic Acid	Blood and Blood Forming Organs	Antifibrinolytic agent	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.6373425 %)	Approved	27742486
DrugRepV_2909	Estrone	Genito Urinary System and Sex Hormones	Perimenopausal and postmenopausal symptoms	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.6830838 %)	Approved	27742486
DrugRepV_2910	Orlistat	Alimentary Tract and Metabolism	Obesity	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.7414562 %)	Approved, Investigational	27742486
DrugRepV_2911	Sulfanilamide	Antiinfectives For Systemic Use	Vulvovaginitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.7841731 %)	Approved	27742486
DrugRepV_2912	Prednisone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Allergic rhinitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.8505525 %)	Approved, Vet approved	27742486
DrugRepV_2913	Noradrenaline Bitartrate Monohydrate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.8741533 %)	NA	27742486
DrugRepV_2914	Pramipexole	Nervous System	Parkinson's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-10.257475 %)	Approved, Investigational	27742486
DrugRepV_2915	Glyburide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-10.433422 %)	Approved	27742486
DrugRepV_2916	Chlorothiazide	Cardiovascular agents	Edema associated with congestive heart failure, hepatic cirrhosis and hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-10.451156 %)	Approved	27742486
DrugRepV_2917	Terbinafine	Dermatologicals	Toenail or Fingernail infections (Fungal) | Tinea capitis (scalp ringworm) | Tinea corporis (body ringworm) or tinea cruris (jock itch)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-10.718001 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2918	Tioconazole	Dermatologicals; Genito Urinary System and Sex Hormones	Vulvovaginal candidiasis (moniliasis)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-10.954794 %)	Approved	27742486
DrugRepV_2919	Doxifluridine	Anticancer	Stomach cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-11.000576 %)	Investigational	27742486
DrugRepV_2920	Fenticonazole nitrate	Dermatologicals	Fungal infections (Vulvovaginal candidiasis)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-11.000576 %)	Experimental	27742486
DrugRepV_2921	Busulfan	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-11.084498 %)	Approved	27742486
DrugRepV_2922	Amphotericin B	Antiinfectives For Systemic Use	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-11.133117 %)	Approved	27742486
DrugRepV_2923	Phenylbutazone	Musculo-Skeletal System	Backache | Ankylosing spondylitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-11.578798 %)	Approved, Vet approved	27742486
DrugRepV_2924	Trifluoperazine Dihydrochloride	Nervous System	Schizophrenia and other psychotic disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-11.74809 %)	Approved	27742486
DrugRepV_2925	Ibuprofen	Musculo-Skeletal System	Rheumatoid arthritis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-11.93197 %)	Approved	27742486
DrugRepV_2926	Alendronate	Musculo-Skeletal System	Paget disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-11.958789 %)	Approved	27742486
DrugRepV_2927	Amiodarone Hydrochloride	Cardiovascular agents	Anginal and Arrhythmia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-12.235293 %)	Approved	27742486
DrugRepV_2928	Paliperidone	Nervous System	Schizophrenia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-12.545451 %)	Approved	27742486
DrugRepV_2929	Biperiden Hydrochloride	Nervous System	Parkinson disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-12.770433 %)	Approved	27742486
DrugRepV_2930	Nilvadipine	Cardiovascular agents	Angina | Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-12.889881 %)	Approved	27742486
DrugRepV_2931	Adenosine	Cardiovascular agents	Arrhythmia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-12.932123 %)	Approved	27742486
DrugRepV_2932	Riluzole	Nervous System	Amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-13.776241 %)	Approved, Investigational	27742486
DrugRepV_2933	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-14.433754 %)	Approved	27742486
DrugRepV_2934	Chloramphenicol	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-14.926902 %)	Approved	27742486
DrugRepV_2935	Monobenzone	Dermatologicals	Vitiligo	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-16.860885 %)	Approved	27742486
DrugRepV_2936	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Neutral red uptake assay	Decrease (50 %)	Approved	20336760
DrugRepV_2937	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Neutral red uptake assay	Decrease (50 %)	Approved	20336760
DrugRepV_2938	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Neutral red uptake assay	Decrease (50 %)	Approved	20336760
DrugRepV_2939	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Neutral red uptake assay	Decrease (90 %)	Approved	20336760
DrugRepV_2940	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Neutral red uptake assay	Decrease (90 %)	Approved	20336760
DrugRepV_2941	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Neutral red uptake assay	Decrease (90 %)	Approved	20336760
DrugRepV_2942	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease (3 logs)	Approved	20336760
DrugRepV_2943	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease (3 logs)	Approved	20336760
DrugRepV_2944	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease (3 logs)	Approved	20336760
DrugRepV_2945	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease (94 %)	Approved	20336760
DrugRepV_2946	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease (65 %)	Approved	20336760
DrugRepV_2947	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease (70 %)	Approved	20336760
DrugRepV_2948	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Real-time PCR	Decrease	Approved	20336760
DrugRepV_2949	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Real-time PCR	Decrease	Approved	20336760
DrugRepV_2950	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Real-time PCR	Decrease	Approved	20336760
DrugRepV_2951	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	DRDE-06	NA	Immunoflourescence assay	Decrease	Approved	20336760
DrugRepV_2952	Tetracycline	Antiinfectives For Systemic Use	Bacterial infections (Rocky Mountain spotted fever | Typhus fever | Tick fevers | Q fever | Rickettsialpox | Brill-Zinsser disease)	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (2.76 ÌÑ 107 pfu/ml)	Approved	25970853
DrugRepV_2953	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (1.50 ÌÑ 107 pfu/ml)	Approved	25970853
DrugRepV_2954	Rolitetracycline	Antiinfectives For Systemic Use	Bacterial infection	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (3.76 ÌÑ 107 pfu/ml)	Approved	25970853
DrugRepV_2955	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (0.96 ÌÑ 107 pfu/ml)	Approved	25970853
DrugRepV_2956	Aciclovir	Antiinfectives For Systemic Use	Viral infection	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (2.30 ÌÑ 107 pfu/ml)	Approved	25970853
DrugRepV_2957	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	NA	NA	Approved	25970853
DrugRepV_2958	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	NA	NA	Approved	25970853
DrugRepV_2959	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	25970853
DrugRepV_2960	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	25970853
DrugRepV_2961	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	25970853
DrugRepV_2962	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Enzyme-linked immunosorbent assay	Decrease (51 %)	Approved	25970853
DrugRepV_2963	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Enzyme-linked immunosorbent assay	Decrease (68 %)	Approved	25970853
DrugRepV_2964	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Enzyme-linked immunosorbent assay	Decrease (95 %)	Approved	25970853
DrugRepV_2965	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (68 %)	Approved	25970853
DrugRepV_2966	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (45 %)	Approved	25970853
DrugRepV_2967	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (91 %)	Approved	25970853
DrugRepV_2968	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (71 %)	Approved	25970853
DrugRepV_2969	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (44 %)	Approved	25970853
DrugRepV_2970	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (92 %)	Approved	25970853
DrugRepV_2971	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (43 %)	Approved	25970853
DrugRepV_2972	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (67 %)	Approved	25970853
DrugRepV_2973	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (91 %)	Approved	25970853
DrugRepV_2974	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	MTT assay	Decrease (65 %)	Approved	25970853
DrugRepV_2975	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	MTT assay	Decrease (71.6 %)	Approved	25970853
DrugRepV_2976	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	MTT assay	Decrease (88.2 %)	Approved	25970853
DrugRepV_2977	Apigenin	NA	NA	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	Experimental	22205980
DrugRepV_2978	Chrysin	Plant extract	NA	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	Experimental	22205980
DrugRepV_2979	Naringenin	NA	NA	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	Experimental	22205980
DrugRepV_2980	Silybin	NA	NA	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	Experimental, Investigational	22205980
DrugRepV_2981	Prothipendyl	Nervous System	Dementia | Depression | Schizophrenia | Anxiety Disorders | Psychosomatic Disorders	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	Investigational	22205980
DrugRepV_2982	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	Approved	22205980
DrugRepV_2983	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	Approved	22205980
DrugRepV_2984	6-Azauridine	NA	Cancer	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	NA	22205980
DrugRepV_2985	3-NH2-3-deoxyadenosine	NA	NA	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	NA	22205980
DrugRepV_2986	Apigenin	NA	NA	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	Experimental	22205980
DrugRepV_2987	Chrysin	Plant extract	NA	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	Experimental	22205980
DrugRepV_2988	Naringenin	NA	NA	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	Experimental	22205980
DrugRepV_2989	Silybin	NA	NA	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	Experimental, Investigational	22205980
DrugRepV_2990	Prothipendyl	Nervous System	Dementia | Depression | Schizophrenia | Anxiety Disorders | Psychosomatic Disorders	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	Investigational	22205980
DrugRepV_2991	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	Approved	22205980
DrugRepV_2992	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	Approved	22205980
DrugRepV_2993	6-Azauridine	NA	Cancer	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	NA	22205980
DrugRepV_2994	3-NH2-3-deoxyadenosine	NA	NA	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	NA	22205980
DrugRepV_2995	Flavaglines FL3	Anticancer	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (45 %)	NA	25643977
DrugRepV_2996	Flavaglines FL3	Anticancer	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (50 %)	NA	25643977
DrugRepV_2997	Flavaglines FL23	Anticancer	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (25 %)	NA	25643977
DrugRepV_2998	Flavaglines FL23	Anticancer	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (40 %)	NA	25643977
DrugRepV_2999	Sulfonyl Amidine	NA	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (10 %)	NA	25643977
DrugRepV_3000	Sulfonyl Amidine	NA	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (40 %)	NA	25643977
DrugRepV_3001	Flavaglines FL3	Anticancer	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (50 %)	NA	25643977
DrugRepV_3002	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Real-time PCR	Decrease (100 %)	Approved	28600536
DrugRepV_3003	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Plaque assay	Decrease (100 %)	Approved	28600536
DrugRepV_3004	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Western blot	Decrease (100 %)	Approved	28600536
DrugRepV_3005	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Western blot	Decrease (100 %)	Approved	28600536
DrugRepV_3006	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Western blot	Decrease (100 %)	Approved	28600536
DrugRepV_3007	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Rluc assay	Decrease (1x 103 logs)	Approved	28600536
DrugRepV_3008	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Real-time PCR	Decrease (1x 103 logs)	Approved	28600536
DrugRepV_3014	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Real-time PCR	Decrease (1 log)	Approved	28343845
DrugRepV_3017	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Real-time PCR	Decrease (0.7 log)	Approved	28343845
DrugRepV_3018	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Real-time PCR	Decrease (0.8 log)	Approved	28343845
DrugRepV_3019	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Real-time PCR	Decrease (0.5 log)	Approved	28343845
DrugRepV_3024	Demethoxycurcumin	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease	Phase II	28343845
DrugRepV_3025	Bisdemethoxycurcumin	Plant extract	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease	Early Phase I	28343845
DrugRepV_3026	EF-24	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease	NA	28343845
DrugRepV_3027	FLLL31	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease	NA	28343845
DrugRepV_3033	Demethoxycurcumin	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	Phase II	28343845
DrugRepV_3034	Bisdemethoxycurcumin	Plant extract	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	Early Phase I	28343845
DrugRepV_3035	EF-24	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	NA	28343845
DrugRepV_3036	FLLL31	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	NA	28343845
DrugRepV_3037	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	Approved	28343845
DrugRepV_3038	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Approved	26752081
DrugRepV_3039	Abamectin	NA	Helmintic infection	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Terminated	26752081
DrugRepV_3040	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Approved, Investigational, Vet approved	26752081
DrugRepV_3041	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Investigational	26752081
DrugRepV_3042	Bromocriptine	Nervous System	Parkinson disease	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Approved	26752081
DrugRepV_3043	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Approved	26752081
DrugRepV_3044	Abamectin	NA	Helmintic infection	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Terminated	26752081
DrugRepV_3045	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Approved, Investigational, Vet approved	26752081
DrugRepV_3046	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Investigational	26752081
DrugRepV_3047	Bromocriptine	Nervous System	Parkinson disease	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Approved	26752081
DrugRepV_3048	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (100 %)	Terminated	26752081
DrugRepV_3049	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (100 %)	Approved, Investigational, Vet approved	26752081
DrugRepV_3050	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (87 %)	Approved	26752081
DrugRepV_3051	Amphotericin B	Antiinfectives For Systemic Use	Fungal infection	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (77 %)	Approved	26752081
DrugRepV_3052	Cerivastatin	Cardiovascular agents	Rhabdomyolysis	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (70 %)	Approved	26752081
DrugRepV_3053	Bromocriptine	Nervous System	Parkinson disease	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (65 %)	Approved	26752081
DrugRepV_3054	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (40 %)	Investigational	26752081
DrugRepV_3055	Clotrimazole	Dermatologicals	Fungal infection	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (30 %)	Approved	26752081
DrugRepV_3056	Bifonazole	Dermatologicals	Fungal infection	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (22 %)	Approved	26752081
DrugRepV_3057	Miconazole	Alimentary Tract And Metabolism; Dermatologicals; Genito Urinary System; Sex Hormones; Antiinfective	Fungal infections (Tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment o	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (22 %)	Approved, Investigational, Vet approved	26752081
DrugRepV_3058	Atovaquone	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (20 %)	Approved	26752081
DrugRepV_3059	Triclabendazole	Antiparasitic products, Insectisides and Repellents	Fascioliasis (Parasitic infection)	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (20 %)	Approved, Investigational	26752081
DrugRepV_3060	Efavirenz	Antiinfectives For Systemic Use	Acquired immuno deficiency syndrome	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (10 %)	Approved	26752081
DrugRepV_3061	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Renilla luciferase assay	No significant effect (No significant effect %)	Terminated	26752081
DrugRepV_3062	Amphotericin B	Antiinfectives For Systemic Use	Fungal infection	Chikungunya virus	CHIKV-Rluc	NA	Renilla luciferase assay	No significant effect (90 %)	Approved	26752081
DrugRepV_3063	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	CHIKV-Rluc	NA	Renilla luciferase assay	No significant effect (No significant effect %)	Approved	26752081
DrugRepV_3064	Bromocriptine	Nervous System	Parkinson disease	Chikungunya virus	CHIKV-Rluc	NA	Renilla luciferase assay	No significant effect (3 %)	Approved	26752081
DrugRepV_3065	Cerivastatin	Cardiovascular agents	Rhabdomyolysis	Chikungunya virus	CHIKV-Rluc	NA	Renilla luciferase assay	No significant effect (10 %)	Approved	26752081
DrugRepV_3066	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Northern blot	Decrease	Terminated	26752081
DrugRepV_3067	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Chikungunya virus	CHIKV-Rluc	NA	Northern blot	Decrease	Approved, Investigational, Vet approved	26752081
DrugRepV_3068	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Western blot	Decrease	Terminated	26752081
DrugRepV_3069	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Western blot	Decrease	Terminated	26752081
DrugRepV_3070	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Chikungunya virus	CHIKV-Rluc	NA	Western blot	Decrease	Approved, Investigational, Vet approved	26752081
DrugRepV_3071	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Chikungunya virus	CHIKV-Rluc	NA	Western blot	Decrease	Approved, Investigational, Vet approved	26752081
DrugRepV_3072	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Western blot	Decrease	Terminated	26752081
DrugRepV_3073	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Western blot	Decrease	Terminated	26752081
DrugRepV_3074	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Chikungunya virus	CHIKV-Rluc	NA	Western blot	Decrease	Approved, Investigational, Vet approved	26752081
DrugRepV_3075	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Chikungunya virus	CHIKV-Rluc	NA	Western blot	Decrease	Approved, Investigational, Vet approved	26752081
DrugRepV_3076	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	Decrease (3.5 Log)	Terminated	26752081
DrugRepV_3077	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	Decrease (5.2 Log)	Approved	26752081
DrugRepV_3078	Bromocriptine	Nervous System	Parkinson disease	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	No significant effect (No significant effect Log)	Approved	26752081
DrugRepV_3079	Cerivastatin	Cardiovascular agents	Rhabdomyolysis	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	No significant effect (No significant effect Log)	Approved	26752081
DrugRepV_3080	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	No significant effect (No significant effect Log)	Investigational	26752081
DrugRepV_3081	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	Decrease (3.5 Log)	Approved, Investigational, Vet approved	26752081
DrugRepV_3082	Abamectin	NA	Helmintic infection	Chikungunya virus	NA	NA	Plaque assay	Decrease (2 Log)	Terminated	26752081
DrugRepV_3083	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	NA	NA	Plaque assay	Decrease (3.3 Log)	Approved	26752081
DrugRepV_3084	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Chikungunya virus	NA	NA	Plaque assay	Decrease (3 Log)	Approved, Investigational, Vet approved	26752081
DrugRepV_3085	Abamectin	NA	Helmintic infection	Chikungunya virus	NA	NA	Plaque assay	Decrease (0.3 Log)	Terminated	26752081
DrugRepV_3086	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	NA	NA	Plaque assay	Decrease (1.2 Log)	Approved	26752081
DrugRepV_3087	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Chikungunya virus	NA	NA	Plaque assay	Decrease (0.2 Log)	Approved, Investigational, Vet approved	26752081
DrugRepV_3088	Nigericin Sodium	Antibiotics	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (100 %)	NA	23275491
DrugRepV_3089	Dipterocarpol	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (100 %)	NA	23275491
DrugRepV_3090	Anisomycin	Antibacterial	Bacterial infection	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.96 %)	Experimental	23275491
DrugRepV_3091	Aloe-emodin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.89 %)	NA	23275491
DrugRepV_3092	Retrorsine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.84 %)	NA	23275491
DrugRepV_3093	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.82 %)	Approved	23275491
DrugRepV_3094	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.76 %)	NA	23275491
DrugRepV_3095	Tetrahydrolipstatin	Alimentary Tract and Metabolism	Obesity	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.73 %)	Approved	23275491
DrugRepV_3096	Tunicamycin B	NA	Bacterial infections	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.7 %)	Experimental	23275491
DrugRepV_3097	Corydaline	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.69 %)	NA	23275491
DrugRepV_3098	Ellagic Acid	Antioxidant and Anti-proliferative	Follicular Lymphoma, brain injury in intrauterine growth restricted babies, obese adolescents, and solar lentigines	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.61 %)	Investigational	23275491
DrugRepV_3099	Lycorine Hydrochloride	Antiviral, Antimalarial, Anticancer and Antiinflammatory	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.59 %)	NA	23275491
DrugRepV_3100	Usnic Acid	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.54 %)	NA	23275491
DrugRepV_3101	Rhapontin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.53 %)	NA	23275491
DrugRepV_3102	Emetine Dihydrochloride	Antiparasitic products, Insectisides and Repellents	Protozoal disease	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.5 %)	NA	23275491
DrugRepV_3103	Ferutinin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.43 %)	NA	23275491
DrugRepV_3104	Diacetoxyscirpenol	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.27 %)	NA	23275491
DrugRepV_3105	Bleomycin	Antineoplastic and Immunomodulating Agents	Bacterial infection and cancer	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.27 %)	Approved	23275491
DrugRepV_3106	Cycloheximide	Antibacterial	Bacterial infections	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.1 %)	NA	23275491
DrugRepV_3107	Acivicin	NA	Cancer	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.07 %)	Phase I	23275491
DrugRepV_3108	Narasin	Antibacterial	Parasitic and bacterial infections	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (98.89 %)	Experimental	23275491
DrugRepV_3109	Jervine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (98.35 %)	NA	23275491
DrugRepV_3110	Hypocrellin B	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (98.08 %)	NA	23275491
DrugRepV_3111	Valinomycin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (97.79 %)	Experimental	23275491
DrugRepV_3112	Hypocrellin A	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (97.64 %)	NA	23275491
DrugRepV_3113	Menadione	Blood and Blood Forming Organs	Blood clotting | Bone calcification	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (97.53 %)	Approved, Nutraceutical	23275491
DrugRepV_3114	E-64	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (95.94 %)	NA	23275491
DrugRepV_3115	Magnolol	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (95.74 %)	NA	23275491
DrugRepV_3116	Daunorubicin Hydrochloride	Antineoplastic and Immunomodulating Agents	Leukemia	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (95.56 %)	Approved	23275491
DrugRepV_3117	Nonactin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (95.31 %)	NA	23275491
DrugRepV_3118	Antimycin A1	Antifungal	Fungal infections	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (94.99 %)	NA	23275491
DrugRepV_3119	Ochratoxin A	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (94.95 %)	NA	23275491
DrugRepV_3120	Papaverine hydrochloride	Genito Urinary System and Sex Hormones	Impotence | Vasospasms	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (94.76 %)	Approved, Investigational	23275491
DrugRepV_3121	Parthenolide	NA	Allergic Contact Dermatitis	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (93.95 %)	Approved, Investigational	23275491
DrugRepV_3122	Vinblastine Sulfate	Antineoplastic and Immunomodulating Agents	Cancer (Hodgkin lymphoma | Non-Hodgkin's lymphoma |Testicular | Breast | Lung (Non-small cell lung cancer) | Head and neck | Bladder cancers | Melanoma | Soft tissue sarcoma |Kaposi's sarcoma | Mycosis fungoides (t-cell lymphoma) | Choriocarcinoma)	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (93.75 %)	Approved	23275491
DrugRepV_3123	Chelidonine	Plant extract	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (93.22 %)	NA	23275491
DrugRepV_3124	Rottlerin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (92.81 %)	NA	23275491
DrugRepV_3125	Grayanotoxin III	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (91.39 %)	NA	23275491
DrugRepV_3126	Gossypol	NA	Non-small Cell Lung Cancer	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (90.89 %)	Investigational	23275491
DrugRepV_3127	Sanguinarine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (90.83 %)	NA	23275491
DrugRepV_3128	Mithramycin A	Antineoplastic and Immunomodulating Agents	Testicular cancer | Hypercalcemia | Hypercalciuria	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (87.96 %)	Approved	23275491
DrugRepV_3129	Actinomycin D	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (86.92 %)	Approved	23275491
DrugRepV_3130	Cyclopiazonic Acid	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (79.93 %)	NA	23275491
DrugRepV_3131	Harmine Hydrochloride	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (73.68 %)	NA	23275491
DrugRepV_3132	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (50 %)	NA	23275491
DrugRepV_3133	Hypocrellin A	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (50 %)	NA	23275491
DrugRepV_3134	Rottlerin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (50 %)	NA	23275491
DrugRepV_3135	Daunorubicin	Antineoplastic and Immunomodulating Agents	Leukemia	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (50 %)	Approved	23275491
DrugRepV_3136	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Plaque assay	Decrease (4.3 Log)	NA	23275491
DrugRepV_3137	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (2.3 Log)	NA	23275491
DrugRepV_3138	Homoharringtonine	Antineoplastic and Immunomodulating Agents	Chronic myeloid leukemia (CML)	Chikungunya virus	CHIKV-122508	NA	Plaque assay	Decrease (4.3 Log)	Approved, Investigational	23275491
DrugRepV_3139	Homoharringtonine	Antineoplastic and Immunomodulating Agents	Chronic myeloid leukemia (CML)	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (2.3 Log)	Approved, Investigational	23275491
DrugRepV_3140	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (3 Log)	NA	23275491
DrugRepV_3141	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Plaque assay	Decrease (3.5 Log)	NA	23275491
DrugRepV_3142	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (2.8 Log)	NA	23275491
DrugRepV_3143	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (7.8 Log)	NA	23275491
DrugRepV_3144	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (6.4 Log)	NA	23275491
DrugRepV_3145	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Real-time PCR	Decrease (6 (Complete inhibition) Log)	NA	23275491
DrugRepV_3146	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Real-time PCR	Decrease (2 Log)	NA	23275491
DrugRepV_3147	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Real-time PCR	Decrease (2 Log)	NA	23275491
DrugRepV_3148	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Real-time PCR	Decrease (2.4 Log)	NA	23275491
DrugRepV_3149	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Real-time PCR	Decrease (3 Log)	NA	23275491
DrugRepV_3150	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Western blot	Decrease	NA	23275491
DrugRepV_3151	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Western blot	Decrease	NA	23275491
DrugRepV_3152	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Western blot	Decrease	NA	23275491
DrugRepV_3153	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Western blot	Decrease	NA	23275491
DrugRepV_3154	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Western blot	Decrease	NA	23275491
DrugRepV_3155	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Western blot	Decrease	NA	23275491
DrugRepV_3156	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	14670584
DrugRepV_3157	6-Azauridine	NA	Cancer	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	14670584
DrugRepV_3158	Glycyrrhizin	Alimentary Tract and Metabolism	Chronic hepatitis	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Experimental	14670584
DrugRepV_3159	Iota-carrageenan	Plant extract	Common Cold	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	14670584
DrugRepV_3160	Fucoidan	NA	NA	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	14670584
DrugRepV_3161	Dextran Sulphate	Blood and Blood Forming Organs	NA	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	14670584
DrugRepV_3162	IFN-alpha2a	Antineoplastic and Immunomodulating Agents	Hepatitis C virus | Hairy cell leukemia | AIDS-related Kaposi's sarcoma | Leukemia	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	14670584
DrugRepV_3163	IFN-alpha2b	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	14670584
DrugRepV_3164	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (1.8 Log)	Approved	14670584
DrugRepV_3165	6-Azauridine	NA	Cancer	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (1.8 Log)	NA	14670584
DrugRepV_3166	Glycyrrhizin	Alimentary Tract and Metabolism	Chronic hepatitis	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (5.2 Log)	Approved, Experimental	14670584
DrugRepV_3167	IFN-alpha2b	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (5.4 Log)	Approved	14670584
DrugRepV_3168	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (99 %)	Approved	14670584
DrugRepV_3169	6-Azauridine	NA	Cancer	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (99 %)	NA	14670584
DrugRepV_3170	Glycyrrhizin	Alimentary Tract and Metabolism	Chronic hepatitis	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (99 %)	Approved, Experimental	14670584
DrugRepV_3171	IFN-alpha2b	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (99 %)	Approved	14670584
DrugRepV_3172	IFN-alpha2b-Ribavirin	NA	NA	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	14670584
DrugRepV_3173	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	DRDE-06	NA	Virus yield reduction assay	Decrease (50 %)	Approved	21070810
DrugRepV_3174	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	DRDE-06	NA	Virus yield reduction assay	Decrease (50 %)	Approved	21070810
DrugRepV_3175	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	DRDE-06	NA	Virus yield reduction assay	Decrease (50 %)	Approved	21070810
DrugRepV_3176	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	DRDE-06	NA	Virus yield reduction assay	Decrease (50 %)	Approved	21070810
DrugRepV_3177	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	DRDE-06	NA	Virus yield reduction assay	Decrease (50 %)	Approved	21070810
DrugRepV_3178	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	DRDE-06	NA	Plaque assay	Decrease	Approved	21070810
DrugRepV_3179	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	DRDE-06	NA	Real-time PCR	Decrease	Approved	21070810
DrugRepV_3180	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	DRDE-06	NA	Real-time PCR	Decrease	Approved	21070810
DrugRepV_3199	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	No significant effect (No significant reduction log)	Investigational	26384169
DrugRepV_3200	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Flow cytometry	Decrease (90 %)	Investigational	26384169
DrugRepV_3201	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (3 Log)	Investigational	26384169
DrugRepV_3202	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (2 Log)	Investigational	26384169
DrugRepV_3203	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (50 %)	Investigational	26384169
DrugRepV_3204	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (50 %)	Investigational	26384169
DrugRepV_3205	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Western blot	Decrease (Capsid protein Protein expression)	Investigational	26384169
DrugRepV_3206	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Western blot	Decrease (E1 protein Protein expression)	Investigational	26384169
DrugRepV_3207	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Western blot	Decrease (pE2 protein Protein expression)	Investigational	26384169
DrugRepV_3208	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Western blot	Decrease (E2 protein Protein expression)	Investigational	26384169
DrugRepV_3209	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Western blot	Decrease (nsP2 protein Protein expression)	Investigational	26384169
DrugRepV_3210	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Western blot	Decrease (nsP3 protein Protein expression)	Investigational	26384169
DrugRepV_3211	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Real-time PCR	Decrease (2 Log)	Investigational	26384169
DrugRepV_3212	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Real-time PCR	Decrease (2 Log)	Investigational	26384169
DrugRepV_3213	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Cell viability assay	Decrease (25 %)	Investigational	26384169
DrugRepV_3214	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Cell viability assay	Decrease (65 %)	Investigational	26384169
DrugRepV_3215	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Cell viability assay	Decrease (65 %)	Investigational	26384169
DrugRepV_3216	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (1 Log)	Investigational	26384169
DrugRepV_3217	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (2 Log)	Investigational	26384169
DrugRepV_3218	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (1.8 Log)	Investigational	26384169
DrugRepV_3219	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	No significant effect (No significant reduction Log)	Investigational	26384169
DrugRepV_3220	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (1 Log)	Investigational	26384169
DrugRepV_3221	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (0.9 Log)	Investigational	26384169
DrugRepV_3222	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (No significant reduction Log)	Investigational	26384169
DrugRepV_3223	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (1.2 Log)	Investigational	26384169
DrugRepV_3224	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (1.2 Log)	Investigational	26384169
DrugRepV_3225	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VS	NA	Western blot	Decrease (pE2 protein expression Protein expression)	Investigational	26384169
DrugRepV_3226	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VS	NA	Western blot	Decrease (E2 protein expresion Protein expression)	Investigational	26384169
DrugRepV_3227	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Western blot	Decrease (pE2 protein expression Protein expression)	Investigational	26384169
DrugRepV_3228	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Western blot	Decrease (E2 protein expresion Protein expression)	Investigational	26384169
DrugRepV_3229	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VS	NA	Plaque assay	Decrease (1.3 Log)	Investigational	26384169
DrugRepV_3230	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (2.5 Log)	Investigational	26384169
DrugRepV_3231	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (2 Log)	Investigational	26384169
DrugRepV_3232	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Real-time PCR	Decrease (2 Log)	Investigational	26384169
DrugRepV_3233	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (50 %)	Investigational	26384169
DrugRepV_3234	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Indian Ocean strain 899	NA	Colorimetric method	Decrease (50 %)	Investigational	24951535
DrugRepV_3235	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Indian Ocean strain 899	NA	Colorimetric method	Decrease (50 %)	Investigational	24951535
DrugRepV_3236	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	LR2006 OPY1	NA	Colorimetric method	Decrease (50 %)	Investigational	24951535
DrugRepV_3237	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	LR2006 OPY1	NA	Colorimetric method	Decrease (50 %)	Investigational	24951535
DrugRepV_3238	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Italy 2008 (clinical)	NA	Colorimetric method	Decrease (50 %)	Investigational	24951535
DrugRepV_3239	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Italy 2008 (clinical)	NA	Colorimetric method	Decrease (50 %)	Investigational	24951535
DrugRepV_3240	T-1105	NA	Zika virus	Chikungunya virus	Indian Ocean strain 899	NA	Colorimetric method	Decrease (50 %)	NA	24951535
DrugRepV_3241	T-1105	NA	Zika virus	Chikungunya virus	Indian Ocean strain 899	NA	Colorimetric method	Decrease (50 %)	NA	24951535
DrugRepV_3242	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Indian Ocean strain 899	NA	Real-time PCR	Decrease (50 %)	Investigational	24951535
DrugRepV_3243	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Indian Ocean strain 899	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3244	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	LR2006 OPY1	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3245	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Venturini (Italy 2008)	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3246	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Bianchi (Italy 2008)	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3247	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Congo 95 (2011)	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3248	T-1105	NA	Zika virus	Chikungunya virus	Indian Ocean strain 899	NA	Plaque assay	Decrease (50 %)	NA	24951535
DrugRepV_3249	T-1105	NA	Zika virus	Chikungunya virus	Indian Ocean strain 899	NA	Real-time PCR	Decrease (50 %)	NA	24951535
DrugRepV_3250	T-1105	NA	Zika virus	Chikungunya virus	LR2006 OPY1	NA	Real-time PCR	Decrease (50 %)	NA	24951535
DrugRepV_3251	T-1105	NA	Zika virus	Chikungunya virus	Venturini (Italy 2008)	NA	Real-time PCR	Decrease (50 %)	NA	24951535
DrugRepV_3252	T-1105	NA	Zika virus	Chikungunya virus	Bianchi (Italy 2008)	NA	Real-time PCR	Decrease (50 %)	NA	24951535
DrugRepV_3253	T-1105	NA	Zika virus	Chikungunya virus	Congo 95 (2011)	NA	Real-time PCR	Decrease (50 %)	NA	24951535
DrugRepV_3254	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV 899	NA	Real-time PCR	Decrease (95 %)	Investigational	24951535
DrugRepV_3255	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV 899	NA	Real-time PCR	Decrease (98 %)	Investigational	24951535
DrugRepV_3256	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV 899	NA	Real-time PCR	Decrease (88 %)	Investigational	24951535
DrugRepV_3257	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV S27	NA	Survival assay	NA	Investigational	24951535
DrugRepV_3258	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV S27	NA	Survival assay	NA	Investigational	24951535
DrugRepV_3259	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV S27	NA	Real-time PCR	Decrease (3.2 ± 0.1 Log)	Investigational	24951535
DrugRepV_3260	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV S27	NA	Real-time PCR	Decrease (2.3 ± 0.3 Log)	Investigational	24951535
DrugRepV_3261	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res C1-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3262	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res C2-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3263	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res C3-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3264	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res C1-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3265	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res C2-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3266	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res C3-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3267	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res_p7 C1-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3268	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res_p7 C2-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3269	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res_p7 C3-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3270	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res_p7 C1-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3271	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res_p7 C2-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3272	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res_p7 C3-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3273	5-Tetradecyloxy-2-furoic Acid	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3274	Orlistat	Alimentary Tract and Metabolism	Obesity	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved, Investigational	27177310
DrugRepV_3275	Cerulenin	NA	Fungal infection	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved	27177310
DrugRepV_3276	Bafilomycin	Antibiotics	Bacterial infection	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Experimental	27177310
DrugRepV_3277	AnnH18	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3278	AnnH14	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3279	KH-CB19	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3280	Anacardic Acid	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3281	TAE684	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3282	Pimozide	Nervous System	Tourette Disorder	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved	27177310
DrugRepV_3283	Perphenazine	Nervous System	Psychosis | Nausea and vomiting in adults	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved	27177310
DrugRepV_3284	6-Hydroxyflavone	NA	Anxiety-like disorders	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3285	Prenylamine	Cardiovascular agents	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved, Withdrawn	27177310
DrugRepV_3286	Felodipine	Cardiovascular agents	Hypertension	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved, Investigational	27177310
DrugRepV_3287	Alsterpaullone	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Experimental	27177310
DrugRepV_3288	Pazopanib	Antineoplastic and Immunomodulating Agents	Advanced renal cell cancer | Advanced soft tissue sarcoma	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved	27177310
DrugRepV_3289	Axitinib	Antineoplastic and Immunomodulating Agents	Cancer	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved	27177310
DrugRepV_3290	Tivozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Investigational	27177310
DrugRepV_3291	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma | Renal cell carcinoma	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved, Investigational	27177310
DrugRepV_3292	Linifanib	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3298	Anacardic Acid	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (75 %)	NA	27177310
DrugRepV_3299	Bafilomycin	Antibiotics	Bacterial infection	Chikungunya virus	NA	NA	Flow cytometry	Decrease (100 %)	Experimental	27177310
DrugRepV_3300	Cerulenin	NA	Fungal infection	Chikungunya virus	NA	NA	Flow cytometry	Decrease (75 %)	Approved	27177310
DrugRepV_3301	Pimozide	Nervous System	Tourette Disorder	Chikungunya virus	NA	NA	Flow cytometry	Decrease (90 %)	Approved	27177310
DrugRepV_3302	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	NA	NA	Flow cytometry	Decrease (90 %)	Investigational	27177310
DrugRepV_3303	Cerulenin	NA	Fungal infection	Chikungunya virus	NA	NA	Real-time PCR	Decrease (100 %)	Approved	27177310
DrugRepV_3304	5-Tetradecyloxy-2-furoic Acid	NA	NA	Chikungunya virus	NA	NA	Real-time PCR	Decrease (100 %)	NA	27177310
DrugRepV_3305	Pimozide	Nervous System	Tourette Disorder	Chikungunya virus	NA	NA	Real-time PCR	Decrease (75 %)	Approved	27177310
DrugRepV_3306	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	NA	NA	Real-time PCR	Decrease (50 %)	Investigational	27177310
DrugRepV_3307	Cerulenin	NA	Fungal infection	Chikungunya virus	NA	NA	Real-time PCR	Decrease (100 %)	Approved	27177310
DrugRepV_3308	5-Tetradecyloxy-2-furoic Acid	NA	NA	Chikungunya virus	NA	NA	Real-time PCR	Decrease (100 %)	NA	27177310
DrugRepV_3309	Pimozide	Nervous System	Tourette Disorder	Chikungunya virus	NA	NA	Real-time PCR	Decrease (80 %)	Approved	27177310
DrugRepV_3310	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	NA	NA	Real-time PCR	Decrease (80 %)	Investigational	27177310
DrugRepV_3311	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	C21	NA	Survival assay	NA	Investigational	27177310
DrugRepV_3312	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	C21	NA	Plaque assay	No significant reduction (0.9 Log)	Investigational	27177310
DrugRepV_3313	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	C21	NA	Plaque assay	Decrease (1.2 Log)	Investigational	27177310
DrugRepV_3314	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	C21	NA	Plaque assay	No significant reduction (0.8 Log)	Investigational	27177310
DrugRepV_3315	Pimozide	Nervous System	Tourette Disorder	Chikungunya virus	C21	NA	Plaque assay	No significant reduction (0.5 Log)	Approved	27177310
DrugRepV_3316	5-Tetradecyloxy-2-furoic Acid	NA	NA	Chikungunya virus	C21	NA	Plaque assay	No significant reduction (0.2 Log)	NA	27177310
DrugRepV_3550	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Chikungunya virus	Asian strain	NA	Real-time PCR	Decrease (50 %)	Approved	30455237
DrugRepV_3551	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Chikungunya virus	Asian strain	NA	Yield reduction assay	Decrease (50 %)	Approved	30455237
DrugRepV_3552	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Asian strain	NA	Real-time PCR	Decrease (50 %)	Approved	30455237
DrugRepV_3553	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Asian strain	NA	Yield reduction assay	Decrease (50 %)	Approved	30455237
DrugRepV_3554	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	Asian strain	NA	Real-time PCR	Decrease (50 %)	Approved	30455237
DrugRepV_3555	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Chikungunya virus	Asian strain	NA	Yield reduction assay	Decrease (50 %)	Approved	30455237
DrugRepV_3556	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Chikungunya virus	Asian strain	NA	Survival assay	Increase	Approved	30455237
DrugRepV_3557	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved	30354193
DrugRepV_3558	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved	30354193
DrugRepV_3559	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved	30354193
DrugRepV_3560	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Investigational	30354193
DrugRepV_3561	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Investigational	30354193
DrugRepV_3562	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Investigational	30354193
DrugRepV_3563	IFN-alpha2a	Antineoplastic and Immunomodulating Agentss	Hepatitis C virus | Hairy cell leukemia | AIDS-related Kaposi's sarcoma | Leukemia	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	30354193
DrugRepV_3564	IFN-alpha2a	Antineoplastic and Immunomodulating Agentss	Hepatitis C virus | Hairy cell leukemia | AIDS-related Kaposi's sarcoma | Leukemia	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	30354193
DrugRepV_3565	IFN-alpha2a	Antineoplastic and Immunomodulating Agentss	Hepatitis C virus | Hairy cell leukemia | AIDS-related Kaposi's sarcoma | Leukemia	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	30354193
DrugRepV_3690	BCX4430	NA	Ebola virus	Chikungunya virus	AF 15561	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_4103	2-(4-tert-butylphenyl)-N-[(E)-(3,4-diethoxyphenyl)methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4104	2-(4-tert-butylphenyl)-N-[(E)-(3,5-dibromo-4-methoxyphenyl)methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4105	2-(4-tert-butylphenyl)-N-[(E)-[4-(diethylamino)-2-hydroxyphenyl]methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4106	2-(4-tert-butylphenyl)-N-[(E)-[4-(trifluoromethyl)phenyl]methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4107	2-(4-tert-butylphenyl)-N-[(E)-[4-(methylsulfanyl)phenyl]methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4108	2-(4-tert-butylphenyl)-N-[(E)-(4-methylphenyl)methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4109	2-(4-tert-butylphenyl)-N-[(1E)-2-[(1-methylnaphthalen-2-yl)oxy]ethylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4110	2-(4-tert-butylphenyl)-N-[(E)-[4-(propan-2-yl)phenyl]methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4111	2-(4-tert-butylphenyl)-N-[(1E)-1-phenylpropylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4112	N-[(E)-(4-bromophenyl)methylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4113	N-[(E)-(4-hydroxyphenyl)methylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4114	N-[(E)-(4-cyclohexylphenyl)methylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4115	N-[(1E)-1-(4-methoxyphenyl)ethylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4116	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(3,4-diethoxyphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4117	Coumarin A	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (50 %)	NA	28100218
DrugRepV_4118	Coumarin B	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (50 %)	NA	28100218
DrugRepV_4119	Lupeol Acetate 26SK001	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (50 %)	NA	28100218
DrugRepV_4120	Voacangine 26SK002	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (50 %)	NA	28100218
DrugRepV_4121	Coumarin A	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (44 %)	NA	28100218
DrugRepV_4122	Coumarin B	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (92.5 %)	NA	28100218
DrugRepV_4123	Lupeol Acetate 26SK001	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (4.1 %)	NA	28100218
DrugRepV_4124	Voacangine 26SK002	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (0.4 %)	NA	28100218
DrugRepV_4125	3-{3-[(1E)-1-(hydroxyimino)ethyl]phenyl}-5-methyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4126	3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-5-methyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4127	5-ethyl-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4128	3-(3-acetylphenyl)-5-ethyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4129	5-(aminomethyl)-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4130	3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-5-sulfanyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4131	3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-5-(methylsulfanyl)-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4132	3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-5-(methylamino)-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4133	5-ethyl-3-{3-[(1E)-1-{[2-(4-methylpiperazin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4134	5-ethyl-3-{3-[(1E)-1-{[2-(morpholin-4-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4135	5-ethyl-3-{3-[(1E)-1-{[2-(thiomorpholin-4-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4136	3-{3-[(1E)-1-{[2-(diethylamino)ethoxy]imino}ethyl]phenyl}-5-ethyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4137	3-{3-[(1E)-1-{[2-(cyclohexylamino)ethoxy]imino}ethyl]phenyl}-5-ethyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4138	5-ethyl-3-{3-[(1E)-1-{[2-(piperidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4139	5-ethyl-3-{3-[(1E)-1-{[2-(pyrrolidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4140	3-{3-[(1E)-1-({2-[4-(dimethylamino)piperidin-1-yl]ethoxy}imino)ethyl]phenyl}-5-ethyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4141	5-ethyl-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Venturini	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4142	5-ethyl-3-{3-[(1E)-1-{[2-(morpholin-4-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Venturini	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4143	5-ethyl-3-{3-[(1E)-1-{[2-(piperidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Venturini	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4144	5-ethyl-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Congo 95	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4145	5-ethyl-3-{3-[(1E)-1-{[2-(morpholin-4-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Congo 95	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4146	5-ethyl-3-{3-[(1E)-1-{[2-(piperidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Congo 95	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4147	5-ethyl-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	St. Martin 20235	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4148	5-ethyl-3-{3-[(1E)-1-{[2-(piperidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	St. Martin 20235	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4149	2-(4-tert-butylphenyl)-N-[(E)-(4-ethoxyphenyl)methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4150	2-(4-tert-butylphenyl)-N-[(E)-[4-(trifluoromethyl)phenyl]methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4151	N-[(E)-(4-hydroxyphenyl)methylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4152	N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4153	N-[(1E)-1-(4-methoxyphenyl)ethylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4154	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(3,4-diethoxyphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4155	2-(4-tert-butylphenyl)-N-[(E)-(4-ethoxyphenyl)methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4156	2-(4-tert-butylphenyl)-N-[(E)-(4-hydroxyphenyl)methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4157	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(4-ethoxyphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4158	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(4-methylphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4159	(2E)-3-(4-methylphenyl)-N-[(E)-(4-methylphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4160	(2E)-N-[(E)-(4-methylphenyl)methylidene]-3-phenylprop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4161	(2E)-3-(4-tert-butylphenyl)-N-[(E)-[4-(propan-2-yl)phenyl]methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4162	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(4-tert-butylphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4163	(2E)-3-(4-tert-butylphenyl)-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4164	(2E)-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-3-phenylprop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4165	(2E)-3-(4-tert-butylphenyl)-N-[(E)-phenylmethylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4166	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(4-nitrophenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4167	(2E)-3-(4-tert-butylphenyl)-N-[(1E)-1-(4-chlorophenyl)ethylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4168	(2E)-3-(4-tert-butylphenyl)-N-[(1E)-1-(pyrazin-2-yl)ethylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4169	(2E)-3-(4-tert-butylphenyl)-N-[(1E)-1-(4-ethoxyphenyl)ethylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4170	(2E)-N-[(1E)-1-{[1,1-biphenyl]-4-yl}ethylidene]-3-(4-tert-butylphenyl)prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4171	(2E)-N-[(E)-(4-ethoxyphenyl)methylidene]-3-(4-methylphenyl)prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4172	(2E)-3-(4-tert-butylphenyl)-N-{[4-(trifluoromethyl)phenyl]methyl}prop-2-enamide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4173	(2E)-3-phenyl-N-{[4-(trifluoromethyl)phenyl]methyl}prop-2-enamide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4174	(2E)-N-({[1,1-biphenyl]-4-yl}methyl)-3-(4-tert-butylphenyl)prop-2-enamide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4175	(2E)-N-({[1,1-biphenyl]-4-yl}methyl)-3-phenylprop-2-enamide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4176	3-(4-tert-butylphenyl)-N-[(E)-(4-ethoxyphenyl)methylidene]propanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4177	N-[(E)-(4-ethoxyphenyl)methylidene]-3-phenylpropanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4178	3-(4-tert-butylphenyl)-N-[(E)-(4-methylphenyl)methylidene]propanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4179	N-[(E)-(4-methylphenyl)methylidene]-3-phenylpropanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4180	3-(4-tert-butylphenyl)-N-[(E)-(4-hydroxyphenyl)methylidene]propanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4181	N-[(E)-(4-methylphenyl)methylidene]-3-phenylpropanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4182	3-(4-tert-butylphenyl)-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]propanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4183	N-[(E)-(4-cyclohexylphenyl)methylidene]-3-phenylpropanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4184	1-(4-{2-[1-cyclohexyl-2-(furan-3-yl)-1H-1,3-benzodiazol-5-yl]-1,3-oxazol-5-yl}phenyl)pyrrolidin-2-one	NA	NA	Chikungunya virus	SL10571	NA	MTT assay	Decrease (50 %)	NA	28236746
DrugRepV_4185	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	SL10571	NA	MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_4186	1-(4-{2-[1-cyclohexyl-2-(furan-3-yl)-1H-1,3-benzodiazol-5-yl]-1,3-oxazol-5-yl}phenyl)pyrrolidin-2-one	NA	NA	Chikungunya virus	S27	NA	MTT assay	Decrease (50 %)	NA	28236746
DrugRepV_4187	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	S27	NA	MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_4188	1-(4-{2-[1-cyclohexyl-2-(furan-3-yl)-1H-1,3-benzodiazol-5-yl]-1,3-oxazol-5-yl}phenyl)pyrrolidin-2-one	NA	NA	Chikungunya virus	BaH306	NA	MTT assay	Decrease (50 %)	NA	28236746
DrugRepV_4189	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	BaH306	NA	MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_4190	Phorbol	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4191	Phorbol-12-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	25970561
DrugRepV_4192	Phorbol-12-decanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4193	Phorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4194	Phorbol-13-butyrate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4195	Pphorbol-13-decanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4196	Phorbol-13-tetradecanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4197	Phorbol-12,13-diacetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4198	Phorbol-12,13-dibutyrate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4199	Phorbol-12,13- dihexanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4200	Phorbol-12,13-didecanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4201	4α-phorbol-12,13-didecanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4202	12-O-tetradecanoylphorbol-13-acetate	NA	Cancer	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase II	25970561
DrugRepV_4203	12-O-tetradecanoyl-4?-phorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4204	12-O- tiglylphorbol-13-decanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4205	12-O-(N-methylanthranilate) phorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4206	Phorbol-13,20-diacetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4207	12,13-O,O-dinonanoylphorbol-20-homovanillate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4208	12-O-phenylacetyl-13-O-acetylphorbol-20-homovanillate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4209	Phorbol-12,13,20-triacetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4210	20-oxo-20-deoxyphorbol-12,13-dibutyrate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4211	12-O-tetradecanoyl-20-oxo-20-deoxyphorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4212	12-deoxyphorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4213	13-O-isobutyryl-12-deoxyphorbol-20-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4214	13-O-phenylacetyl-12-deoxyphorbol-20-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4215	Ingenol	Dermatologicals	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4216	Ingenol-3-mebutate	Dermatologicals	Actinic keratosis	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	25970561
DrugRepV_4217	Ingenol-3,20-dibenzoate	Dermatologicals	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4218	Resiniferatoxin	NA	Interstitial cystitis and urinary incontinence	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	25970561
DrugRepV_4219	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	25970561
DrugRepV_4220	Arbidol	NA	NA	Chikungunya virus	LR2006 OPY1	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	21440006
DrugRepV_4221	HZ2a	NA	NA	Chikungunya virus	LR2006 OPY1	NA	Immunoflourescence assay	Decrease (50 %)	NA	21440006
DrugRepV_4222	6-bromo-4-(dimethylaminomethyl)-5-hydroxy-1-methyl-2-(phe- nylsulphonylmethyl)-1H-indole-3-carboxylate	NA	NA	Chikungunya virus	LR2006 OPY1	NA	Immunoflourescence assay	Decrease (50 %)	NA	21440006
DrugRepV_4223	6-bromo- 4-(dimethylaminomethyl)-5-hydroxy-1-methyl-2-(methylphenyl- sulphoxyde)-1H-indole-3-carboxylate	NA	NA	Chikungunya virus	LR2006 OPY1	NA	Immunoflourescence assay	Decrease (50 %)	NA	21440006
DrugRepV_4224	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(4-ethoxyphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4225	3-[(E)-{[2-(4-methylphenyl)-1H-indol-3-yl]methylidene}amino]-1-(2-phenylethyl)thiourea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4226	(2E)-N-[(E)-(4-ethoxyphenyl)methylidene]-3-[4-(propan-2-yl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4227	(2E)-N-[(E)-(4-ethoxyphenyl)methylidene]-3-[4-(trifluoromethyl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4228	(2E)-N-[(E)-(4-ethoxyphenyl)methylidene]-3-(4-methoxyphenyl)prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4229	(2E)-3-{[1,1-biphenyl]-4-yl}-N-[(E)-(4-ethoxyphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4230	(2E)-N-[(E)-(4-methylphenyl)methylidene]-3-[4-(propan-2-yl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4231	(2E)-N-[(E)-(4-methylphenyl)methylidene]-3-[4-(trifluoromethyl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4232	(2E)-3-(4-methoxyphenyl)-N-[(E)-(4-methylphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4233	(2E)-3-{[1,1-biphenyl]-4-yl}-N-[(E)-(4-methylphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4234	(2E)-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-3-[4-(propan-2-yl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4235	(2E)-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-3-[4-(trifluoromethyl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4236	(2E)-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-3-(4-methoxyphenyl)prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4237	(2E)-3-{[1,1-biphenyl]-4-yl}-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4238	(2E)-N-[(E)-(4-hydroxyphenyl)methylidene]-3-[4-(propan-2-yl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4239	N-[(E)-(4-ethoxyphenyl)methylidene]naphthalene-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4240	N-[(E)-(4-ethoxyphenyl)methylidene]quinoline-3-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4241	N-[(E)-(4-ethoxyphenyl)methylidene]quinoline-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4242	N-[(E)-(4-ethoxyphenyl)methylidene]-1H-indole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4243	N-[(E)-(4-ethoxyphenyl)methylidene]-1H-1,3-benzodiazole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4244	N-[(E)-(4-methylphenyl)methylidene]naphthalene-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4245	N-[(E)-(4-methylphenyl)methylidene]quinoline-3-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4246	N-[(E)-(4-methylphenyl)methylidene]quinoline-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4247	N-[(E)-(4-methylphenyl)methylidene]-1H-indole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4248	N-[(E)-(4-methylphenyl)methylidene]-1H-1,3-benzodiazole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4249	N-[(E)-(4-hydroxyphenyl)methylidene]naphthalene-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4250	N-[(E)-(4-hydroxyphenyl)methylidene]quinoline-3-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4251	N-[(E)-(4-hydroxyphenyl)methylidene]quinoline-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4252	N-[(E)-(4-hydroxyphenyl)methylidene]-1H-indole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4253	N-[(E)-(4-hydroxyphenyl)methylidene]-1H-1,3-benzodiazole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4254	N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]naphthalene-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4255	N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]quinoline-3-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4256	N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]quinoline-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4257	N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-1H-indole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4258	N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-1H-1,3-benzodiazole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4259	3-(4-tert-butylphenyl)-N-[(E)-(4-ethoxyphenyl)methylidene]-3-oxopropanehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4260	3-(4-tert-butylphenyl)-N-[(E)-(4-methylphenyl)methylidene]-3-oxopropanehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4261	3-(4-tert-butylphenyl)-N-[(E)-(4-hydroxyphenyl)methylidene]-3-oxopropanehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4262	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-[(E)-[(4-ethoxyphenyl)methylidene]amino]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4263	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-[(E)-[(4-methylphenyl)methylidene]amino]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4264	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-[(E)-[(4-hydroxyphenyl)methylidene]amino]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4265	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-[(E)-[1-(4-cyclohexylphenyl)ethylidene]amino]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4266	1-[(E)-[(4-ethoxyphenyl)methylidene]amino]-3-(2-phenylethyl)thiourea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4267	1-[(E)-[(4-methylphenyl)methylidene]amino]-3-(2-phenylethyl)thiourea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4268	1-[(E)-[(4-hydroxyphenyl)methylidene]amino]-3-(2-phenylethyl)thiourea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4269	1-[(E)-[1-(4-cyclohexylphenyl)ethylidene]amino]-3-(2-phenylethyl)thiourea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4270	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-[(4-ethoxyphenyl)methyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4271	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-[(4-methylphenyl)methyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4272	1-benzyl-3-[(1E)-2-(4-tert-butylphenyl)ethenyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4273	1-[(4-methoxyphenyl)methyl]-3-[(1E)-2-phenylethenyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4274	1-[(4-methylphenyl)methyl]-3-[(1E)-2-phenylethenyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4275	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-(4-methylphenyl)urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4276	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-(4-hydroxyphenyl)urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4277	1-(4-methylphenyl)-3-[(1E)-2-phenylethenyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4278	1-(4-hydroxyphenyl)-3-[(1E)-2-phenylethenyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4279	N-[(2E)-3-(4-tert-butylphenyl)prop-2-enoyl]-4-ethoxybenzohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4280	N-[(2E)-3-(4-tert-butylphenyl)prop-2-enoyl]-4-methylbenzohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4281	2-[(1E)-2-(4-tert-butylphenyl)ethenyl]-5-(4-ethoxyphenyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4282	2-[(1E)-2-(4-tert-butylphenyl)ethenyl]-5-(4-methylphenyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4283	2-[2-(4-tert-butylphenyl)ethyl]-5-(4-ethoxyphenyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4284	2-[2-(4-tert-butylphenyl)ethyl]-5-(4-methylphenyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4285	2-(4-ethoxyphenyl)-5-(2-phenylethyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4286	2-(4-methylphenyl)-5-(2-phenylethyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4287	4-{5-[2-(4-tert-butylphenyl)ethyl]-1,3,4-oxadiazol-2-yl}phenol	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4288	2-[(4-tert-butylphenyl)methyl]-5-(4-ethoxyphenyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4289	2-[(4-tert-butylphenyl)methyl]-5-(4-methylphenyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4290	4-(4-methylphenyl)-1-(2-phenylethyl)-1H-1,2,3-triazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4291	(2E)-3-(4-tert-butylphenyl)-N-(5-methyl-1H-1,3-benzodiazol-2-yl)prop-2-enamide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4292	(2E)-N-(1H-1,3-benzodiazol-2-yl)-3-(4-tert-butylphenyl)prop-2-enamide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4293	3-(4-tert-butylphenyl)-N-(5-methyl-1H-1,3-benzodiazol-2-yl)propanamide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4294	N-(1H-1,3-benzodiazol-2-yl)-3-(4-tert-butylphenyl)propanamide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4295	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	Approved	29499487
DrugRepV_4296	Piperazine	Antiparasitic products, Insectisides and Repellents	Parasitic infections (Ascariasis)	Chikungunya virus	DRDE-07	NA	Immunoflourescence assay	Decrease	Approved, Vet approved	28842264
DrugRepV_4297	Piperazine	Antiparasitic products, Insectisides and Repellents	Parasitic infections (Ascariasis)	Chikungunya virus	DRDE-07	NA	Plaque reduction assay	Decrease (81 %)	Approved, Vet approved	28842264
DrugRepV_4298	Baicalein	Plant extract	Influenza	Chikungunya virus	NA	NA	NA	Decrease (50 %)	Phase II	27460167
DrugRepV_4299	Fisetin	NA	Frail Elderly Syndrome	Chikungunya virus	NA	NA	NA	Decrease (50 %)	Experimental	27460167
DrugRepV_4300	Quercetagetin	NA	NA	Chikungunya virus	NA	NA	NA	Decrease (50 %)	NA	27460167
DrugRepV_4301	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	NA	NA	NA	Decrease (50 %)	Approved	27460167
DrugRepV_5387	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Chikungunya virus	NA	NA	NA	Decrease (50 %)	Investigational	31307979
DrugRepV_7976	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	Chikungunya virus	S2.1	NA	CPE reduction assay	Decrease (50 %)	Investigational	32191995
DrugRepV_7977	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	Chikungunya virus	S2.2	NA	CPE reduction assay	Decrease (50 %)	Investigational	32191995
DrugRepV_7978	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	Chikungunya virus	S2.3	NA	CPE reduction assay	Decrease (50 %)	Investigational	32191995
DrugRepV_7979	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	Chikungunya virus	S3	NA	CPE reduction assay	Decrease (50 %)	Investigational	32191995
DrugRepV_7980	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	Chikungunya virus	S4.1	NA	CPE reduction assay	Decrease (50 %)	Investigational	32191995
DrugRepV_7981	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	Chikungunya virus	S4.3	NA	CPE reduction assay	Decrease (50 %)	Investigational	32191995
DrugRepV_7982	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	Chikungunya virus	S5	NA	CPE reduction assay	Decrease (50 %)	Investigational	32191995
DrugRepV_7983	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	Chikungunya virus	S7	NA	CPE reduction assay	Decrease (50 %)	Investigational	32191995
DrugRepV_7984	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	Chikungunya virus	S8	NA	CPE reduction assay	Decrease (50 %)	Investigational	32191995
DrugRepV_7985	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	Chikungunya virus	S9	NA	CPE reduction assay	Decrease (50 %)	Investigational	32191995
DrugRepV_8279	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple myeloma	Chikungunya virus	122508	NA	NA	Decrease (50 %)	Approved	32469886
DrugRepV_8280	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple myeloma	Chikungunya virus	122508	NA	NA	Decrease (50 %)	Approved	32469886
DrugRepV_8281	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple myeloma	Chikungunya virus	122508	NA	NA	Decrease (50 %)	Approved	32469886
DrugRepV_8457	Berberine	NA	Parasitic and fungal infection	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Approved	30641880
DrugRepV_8459	Berberine	NA	Parasitic and fungal infection	Enterovirus	H	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28081706
DrugRepV_8460	Berberine	NA	Parasitic and fungal infection	Enterovirus	SHZH98	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28081706
DrugRepV_8461	Berberine	NA	Parasitic and fungal infection	Enterovirus	JS-52	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28081706
DrugRepV_8462	Berberine	NA	Parasitic and fungal infection	Enterovirus	BrCr	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28081706
DrugRepV_8467	Berberine	NA	Parasitic and fungal infection	Influenza virus	NA		XTT assay	Decrease (50 %)	Approved	32245183
DrugRepV_8468	Berberine	NA	Parasitic and fungal infection	Influenza virus	NA		XTT assay	Decrease (50 %)	Approved	32245183
DrugRepV_8469	Berberine	NA	Parasitic and fungal infection	Influenza virus	NA		XTT assay	Decrease (50 %)	Approved	32245183
DrugRepV_8470	Berberine	NA	Parasitic and fungal infection	Influenza virus	NA		XTT assay	Decrease (50 %)	Approved	32245183
DrugRepV_8471	Berberine	NA	Parasitic and fungal infection	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved	21295891
DrugRepV_8472	Berberine	NA	Parasitic and fungal infection	Influenza virus	NA		NA	Decrease (50 %)	Approved	30099043